<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Neuropsychiatr Dis Treat</journal-id><journal-id journal-id-type="iso-abbrev">Neuropsychiatr Dis Treat</journal-id><journal-id journal-id-type="publisher-id">Neuropsychiatric Disease and Treatment</journal-id><journal-title-group><journal-title>Neuropsychiatric Disease and Treatment</journal-title></journal-title-group><issn pub-type="ppub">1176-6328</issn><issn pub-type="epub">1178-2021</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29343962</article-id><article-id pub-id-type="pmc">5751804</article-id><article-id pub-id-type="doi">10.2147/NDT.S146840</article-id><article-id pub-id-type="publisher-id">ndt-14-103</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Weiller</surname><given-names>Emmanuelle</given-names></name><xref ref-type="aff" rid="af1-ndt-14-103">1</xref><xref ref-type="corresp" rid="c1-ndt-14-103"/></contrib><contrib contrib-type="author"><name><surname>Weiss</surname><given-names>Catherine</given-names></name><xref ref-type="aff" rid="af2-ndt-14-103">2</xref></contrib><contrib contrib-type="author"><name><surname>Watling</surname><given-names>Christopher P</given-names></name><xref ref-type="aff" rid="af3-ndt-14-103">3</xref></contrib><contrib contrib-type="author"><name><surname>Edge</surname><given-names>Christopher</given-names></name><xref ref-type="aff" rid="af3-ndt-14-103">3</xref></contrib><contrib contrib-type="author"><name><surname>Hobart</surname><given-names>Mary</given-names></name><xref ref-type="aff" rid="af2-ndt-14-103">2</xref></contrib><contrib contrib-type="author"><name><surname>Eriksson</surname><given-names>Hans</given-names></name><xref ref-type="aff" rid="af1-ndt-14-103">1</xref></contrib><contrib contrib-type="author"><name><surname>Fava</surname><given-names>Maurizio</given-names></name><xref ref-type="aff" rid="af4-ndt-14-103">4</xref><xref ref-type="aff" rid="af5-ndt-14-103">5</xref><xref ref-type="aff" rid="af6-ndt-14-103">6</xref></contrib></contrib-group><aff id="af1-ndt-14-103">
<label>1</label>H. Lundbeck A/S, Valby, Copenhagen, Denmark</aff><aff id="af2-ndt-14-103">
<label>2</label>Otsuka Pharmaceutical Development &#x00026; Commercialization Inc., Princeton, NJ, USA</aff><aff id="af3-ndt-14-103">
<label>3</label>Cambridge Medical Communication Ltd, Cambridge, UK</aff><aff id="af4-ndt-14-103">
<label>4</label>Division of Clinical Research of the MGH Research Institute</aff><aff id="af5-ndt-14-103">
<label>5</label>Department of Psychiatry</aff><aff id="af6-ndt-14-103">
<label>6</label>Clinical Trials Network &#x00026; Institute (CTNI), Massachusetts General Hospital, Boston, MA, USA</aff><author-notes><corresp id="c1-ndt-14-103">Correspondence: Emmanuelle Weiller, H. Lundbeck A/S, Ottiliavej 9, 2500 Valby, Denmark, Tel +33 6 8042 1831, Email <email>emmanuelle.weiller@gmail.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>29</day><month>12</month><year>2017</year></pub-date><volume>14</volume><fpage>103</fpage><lpage>115</lpage><permissions><copyright-statement>&#x000a9; 2018 Weiller et al. This work is published and licensed by Dove Medical Press Limited</copyright-statement><copyright-year>2018</copyright-year><license><license-p>The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><sec><title>Objective</title><p>Patients with major depressive disorder (MDD) with inadequate response to antidepressant treatment (ADT) may suffer a prolonged loss of functioning. This review aimed to determine if self-rated functional measures are informative in randomized placebo-controlled studies of adjunctive therapy in patients with MDD and inadequate response to ADT.</p></sec><sec><title>Methods</title><p>This was a systematic literature review of articles in any language from the MEDLINE database published between January 1990 and March 2017. Eligible studies met the following criteria: patients with MDD; inadequate response to at least one ADT; adjunctive therapy (pharmacological or otherwise) to ADT; placebo control group; randomized controlled trial or a post hoc analysis of a randomized controlled trial; reported a self-rated functioning scale. Study characteristics and functioning efficacy data were extracted.</p></sec><sec><title>Results</title><p>A total of 2,090 discrete records were screened, 293 full-text articles were assessed for eligibility, and 26 studies were included. All studies were acute (6&#x02013;12 weeks) except for one 52-week study. The only self-rated functioning scale used in the included studies was the Sheehan Disability Scale (SDS). Of the 13 adjunctive agents identified, aripiprazole, brexpiprazole, edivoxetine, and risperidone improved functioning versus placebo (<italic>p</italic>&#x0003c;0.05), as measured by the SDS total or mean score. On the SDS &#x0201c;work/studies&#x0201d; item, only aripiprazole had a statistically significant benefit, in one study out of four. Thus, where a benefit was observed on the SDS total or mean, this was generally driven by improvement on the &#x0201c;social life&#x0201d; and &#x0201c;family life&#x0201d; items. A limitation of the review is that it only considered published literature from one database.</p></sec><sec><title>Conclusion</title><p>The SDS, a self-rated functional measure, is informative in acute randomized placebo-controlled studies of adjunctive therapy in patients with MDD and inadequate response to ADT. However, the item that measures work performance may be less relevant to this population than the items that measure social and family life.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>depression</kwd><kwd>antidepressant</kwd><kwd>adjunct</kwd><kwd>Sheehan Disability Scale</kwd><kwd>functional</kwd><kwd>work</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Major depressive disorder (MDD) is characterized by symptoms including depressed mood and a loss of interest or pleasure in activities.<xref rid="b1-ndt-14-103" ref-type="bibr">1</xref> As a consequence of depressive symptoms, patients with MDD typically have impaired functioning across multiple domains, including work, social, and family functioning.<xref rid="b2-ndt-14-103" ref-type="bibr">2</xref>,<xref rid="b3-ndt-14-103" ref-type="bibr">3</xref> For example, depressive symptoms are associated with reduced marital quality, reduced work performance, and lower earnings.<xref rid="b2-ndt-14-103" ref-type="bibr">2</xref></p><p>Key goals for patients with MDD experiencing a depressive episode are remission and full recovery.<xref rid="b4-ndt-14-103" ref-type="bibr">4</xref>,<xref rid="b5-ndt-14-103" ref-type="bibr">5</xref> Recovery should be considered in broad terms, encompassing work, social, and family functioning as well as improvement of depressive symptoms.<xref rid="b6-ndt-14-103" ref-type="bibr">6</xref>,<xref rid="b7-ndt-14-103" ref-type="bibr">7</xref> Indeed, patients with MDD consider a return to normal levels of functioning as one of the most important factors in defining remission from depression.<xref rid="b8-ndt-14-103" ref-type="bibr">8</xref> Although numerous standardized assessments are available to monitor functioning outcomes in the clinic and in research, functioning scales are used less frequently and less consistently than symptom severity scales.<xref rid="b9-ndt-14-103" ref-type="bibr">9</xref> Furthermore, functioning may be less responsive to treatment than symptoms, meaning that functional improvement can lag behind symptomatic outcomes.<xref rid="b10-ndt-14-103" ref-type="bibr">10</xref>,<xref rid="b11-ndt-14-103" ref-type="bibr">11</xref></p><p>Despite being the mainstay of pharmacological treatment for MDD, more than half of patients do not respond to antidepressant treatment (ADT), as shown by the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study.<xref rid="b12-ndt-14-103" ref-type="bibr">12</xref> Patients with inadequate response to ADT have a prolonged loss of functioning and a lower likelihood of employment than those patients who do respond.<xref rid="b13-ndt-14-103" ref-type="bibr">13</xref>,<xref rid="b14-ndt-14-103" ref-type="bibr">14</xref> Treatment strategies for patients with inadequate response to an optimized dose of ADT include switching to another antidepressant, combining the initial antidepressant with a second antidepressant that has a different mode of action, or augmenting the antidepressant with a non-antidepressant drug.<xref rid="b4-ndt-14-103" ref-type="bibr">4</xref>,<xref rid="b15-ndt-14-103" ref-type="bibr">15</xref>&#x02013;<xref rid="b18-ndt-14-103" ref-type="bibr">18</xref> Of the various options for augmentation, second-generation antipsychotics are best supported by the evidence.<xref rid="b19-ndt-14-103" ref-type="bibr">19</xref> However, the effects of different adjunctive therapies on patient functioning have not been consistently studied, and it is not clear whether existing measures of functioning are useful among patients with MDD and inadequate response to ADT.</p><p>A recent systematic review investigated the effect of ADT (selective serotonin reuptake inhibitors, serotonin&#x02013;norepinephrine reuptake inhibitors, other antidepressants, and psychotherapies such as cognitive behavior therapy [CBT]) on functional outcomes in MDD.<xref rid="b20-ndt-14-103" ref-type="bibr">20</xref> The review, which excluded clinical studies of adjunctive pharmacotherapies, concluded that functioning improves together with depressive symptoms, but that functional deficits often remain, even among patients who achieve symptomatic remission.<xref rid="b20-ndt-14-103" ref-type="bibr">20</xref> Given the importance of functioning to the overall well-being of patients, the aim of the present systematic literature review was to determine if self-rated functional measures are informative in randomized placebo-controlled studies of adjunctive therapy in patients with MDD and inadequate response to ADT.</p></sec><sec sec-type="methods"><title>Methods</title><p>This systematic review adheres to PRISMA.<xref rid="b21-ndt-14-103" ref-type="bibr">21</xref></p><sec><title>Eligibility criteria</title><p>Studies were included if they were published, randomized, placebo-controlled studies of adjunctive therapy to ADT in patients with MDD and inadequate response to at least one ADT, and reported a self-rated scale of functioning. The literature search was performed on 8 March 2017. Reports were limited to those published on or after 1 January 1990. No language exclusions were applied.</p></sec><sec><title>Search strategy</title><p>The aim of the initial top-level search strategy was to identify studies that satisfied three criteria: 1) the study included patients with MDD; 2) the study was of antidepressant augmentation (with any pharmacological or non-pharmacological approach, such as CBT or deep brain stimulation); and 3) the study included a placebo or sham control group. The US National Library of Medicine&#x02019;s MEDLINE database was searched, via PubMed, using the terms: (depress* OR MDD) AND (adjunct* OR &#x0201c;add-on&#x0201d; OR augment* OR resist* OR refractory OR inadequate OR incomplete OR suboptimal) AND (placebo).</p><p>Following the initial search it became apparent that these terms were likely to miss some publications of olanzapine&#x02013;fluoxetine combination (OFC) studies. OFC is indicated for the treatment of treatment-resistant depression in the US,<xref rid="b22-ndt-14-103" ref-type="bibr">22</xref> and, due to its availability as a single tablet, has been tested against fluoxetine with no need for placebo. Consequently, a second search was performed on 21 March 2017 to capture OFC studies, using the terms: (depress* OR MDD) AND ((olanzapine AND fluoxetine) OR OFC).</p></sec><sec sec-type="methods"><title>Study selection</title><p>Following the top-level database searches, duplicates were excluded and records were screened to exclude unsuitable articles based on titles and abstracts (<xref ref-type="fig" rid="f1-ndt-14-103">Figure 1</xref>). At this stage, studies were not excluded based on a lack of functioning outcomes, because these are often secondary outcomes not mentioned in abstracts.</p><p>After screening, full-text articles for the remaining records were assessed for eligibility, defined as meeting all of the following criteria: 1) the study included patients with MDD; 2) the patients had inadequate response (by any definition) to at least one ADT; 3) the study investigated an adjunctive therapy to ADT; 4) the study included a placebo or sham control group (or a fluoxetine control group, for OFC); 5) the study was a randomized controlled trial or a post hoc analysis of a randomized controlled trial; and 6) the study reported self-rated functioning scale (or subscale) outcomes. Any self-rated functioning scale was eligible, defined as a scale that reflects the user&#x02019;s actual behavior in the world and is assessed in ways that emphasize doing, performing, maintaining, etc (this is distinct from quality of life &#x02013; a measure based on self-perception and context with an emphasis on satisfaction, contentment, or enjoyment in various aspects of life).<xref rid="b9-ndt-14-103" ref-type="bibr">9</xref> Eligibility assessment was performed in duplicate by two reviewers (split between CPW, CE and JARM), and disagreements were resolved by consensus.</p></sec><sec sec-type="methods"><title>Data extraction</title><p>The following data were extracted for each study, where available: 1) the definition of inadequate response to ADT, both historical (prior to study enrollment) and prospective/ongoing (during the study); 2) the adjunctive treatment (type, dose, and duration); 3) the number of randomized patients; 4) the primary efficacy endpoint and whether or not it was met (in order that failed or negative studies might be identified); 5) the name of the self-rated functioning scale/subscale/items used; 6) self-rated functioning scale scores at baseline (ie, randomization to adjunctive therapy) and the mean change from baseline to the study endpoint (including error measurements, <italic>p</italic>-values versus placebo, and patient numbers); 7) the setting; and 8) the source of funding. Published data were supplemented with data from ClinicalTrials.gov and study protocols/reports, where available. One reviewer extracted the data from included studies (CPW) and a second reviewer checked the extracted data (CE). Disagreements were resolved by checking the original data source. To assess the risk of bias in individual studies, one reviewer (CPW) judged the adequacy of randomization, blinding, and outcome reporting for each study.</p></sec></sec><sec sec-type="results"><title>Results</title><sec sec-type="intro|methods"><title>Study characteristics</title><p>A total of 2,090 discrete records were identified and screened (<xref ref-type="fig" rid="f1-ndt-14-103">Figure 1</xref>).</p><p>Of the 293 full-text articles assessed for eligibility, 26 articles were included, of which 20 reported one or more primary study, and six reported post hoc analyses of already identified studies. In total, these articles described 26 different studies, the characteristics of which are shown in <xref ref-type="table" rid="t1-ndt-14-103">Table 1</xref>. Five of the post hoc analyses were pooled analyses of aripiprazole, and are not discussed further.<xref rid="b23-ndt-14-103" ref-type="bibr">23</xref>&#x02013;<xref rid="b27-ndt-14-103" ref-type="bibr">27</xref> The sixth post hoc analysis reported self-rated functioning data from a risperidone study in more detail than in the primary manuscript.<xref rid="b28-ndt-14-103" ref-type="bibr">28</xref> No sources of bias were identified in individual studies.</p><p>The only self-rated functioning scale used in the included studies was the Sheehan Disability Scale (SDS),<xref rid="b49-ndt-14-103" ref-type="bibr">49</xref>&#x02013;<xref rid="b51-ndt-14-103" ref-type="bibr">51</xref> which was always a secondary or exploratory outcome. The SDS comprises three visual analog scales on which patients self-rate the extent to which symptoms have disrupted their: 1) work/studies (including paid and unpaid volunteer work and training); 2) social life or leisure activities; and 3) family life or home responsibilities. Each of these items is scored from 0 (not at all) to 10 (extremely). Patients can skip the work/studies item if they have not worked/studied in the last week for reasons unrelated to their disorder (eg, retirement); the instructions are unclear for patients who have stopped working because of their depression. The majority of studies calculated the SDS total score, obtained by summing the scores for the three items (range 0 to 30).<xref rid="b37-ndt-14-103" ref-type="bibr">37</xref>&#x02013;<xref rid="b43-ndt-14-103" ref-type="bibr">43</xref>,<xref rid="b45-ndt-14-103" ref-type="bibr">45</xref>,<xref rid="b46-ndt-14-103" ref-type="bibr">46</xref>,<xref rid="b48-ndt-14-103" ref-type="bibr">48</xref> If the work/studies item was unrated, as was the case for 10%&#x02013;35% of patients (in studies where patient numbers by item were available), it was generally unclear whether these patients were excluded from the SDS total score, or whether the SDS total score was calculated by imputing the mean of the other two items in place of the work/studies item. One study calculated the SDS sum of items 2 and 3 score (range 0 to 20), since a large proportion of patients (25%&#x02013;35%) had no work/studies rating.<xref rid="b33-ndt-14-103" ref-type="bibr">33</xref> Six studies calculated the SDS mean score, obtained by taking an average of the item scores for all items that were rated (range 0 to 10).<xref rid="b29-ndt-14-103" ref-type="bibr">29</xref>&#x02013;<xref rid="b32-ndt-14-103" ref-type="bibr">32</xref>,<xref rid="b34-ndt-14-103" ref-type="bibr">34</xref>,<xref rid="b35-ndt-14-103" ref-type="bibr">35</xref> Finally, four studies did not specify how SDS scores were calculated.<xref rid="b36-ndt-14-103" ref-type="bibr">36</xref>,<xref rid="b44-ndt-14-103" ref-type="bibr">44</xref>,<xref rid="b47-ndt-14-103" ref-type="bibr">47</xref></p><p>As can be seen in <xref ref-type="table" rid="t1-ndt-14-103">Table 1</xref>, 13 different adjunctive agents were used across the studies, of which five were second-generation antipsychotics. All were short-term studies (6&#x02013;12 weeks), except for one 52-week study. The minimum number of ADTs (historical plus prospective) to which patients were required to show inadequate response prior to randomization ranged from one to two. Definitions of inadequate response varied, from &#x0201c;investigator judgment&#x0201d;, to strict definitions with qualifying scores on multiple rating scales at multiple time points.</p></sec><sec><title>Efficacy</title><p>Each of the second-generation antipsychotics (aripiprazole, brexpiprazole, cariprazine, olanzapine as OFC [pooled data], and risperidone) had at least one dose that met the primary efficacy endpoint of their respective studies (improvement of depressive symptoms, measured by either Montgomery&#x02013;&#x000c5;sberg Depression Rating Scale total score or 17-item Hamilton Depression Rating Scale total score; <xref ref-type="table" rid="t1-ndt-14-103">Table 1</xref>).<xref rid="b29-ndt-14-103" ref-type="bibr">29</xref>&#x02013;<xref rid="b32-ndt-14-103" ref-type="bibr">32</xref>,<xref rid="b34-ndt-14-103" ref-type="bibr">34</xref>,<xref rid="b35-ndt-14-103" ref-type="bibr">35</xref>,<xref rid="b37-ndt-14-103" ref-type="bibr">37</xref>,<xref rid="b47-ndt-14-103" ref-type="bibr">47</xref>,<xref rid="b48-ndt-14-103" ref-type="bibr">48</xref> The combination of buprenorphine and samidorphan also met its primary efficacy endpoint at one dose.<xref rid="b36-ndt-14-103" ref-type="bibr">36</xref> All other agents failed to meet the primary efficacy endpoint of their respective studies, and were therefore failed or negative studies.</p><p>A summary of the SDS results from the included studies is given in <xref ref-type="table" rid="t2-ndt-14-103">Table 2</xref>. Baseline SDS scores were similar between treatment groups in each study. All groups (active and control) improved numerically from baseline to endpoint, as measured by the SDS total or SDS mean. Most active treatments showed a numerically greater improvement than placebo (except for dexmecamylamine, which had inconsistent results). However, the majority of agents, and studies, failed to show a statistically significant benefit versus placebo on the SDS total or SDS mean. Only four agents demonstrated efficacy (<italic>p</italic>&#x0003c;0.05 versus placebo) on the SDS total or SDS mean in at least one study: aripiprazole, brexpiprazole, edivoxetine, and risperidone. A large variation in placebo response was seen between studies.</p><p>Considering the individual SDS items, only one agent (aripiprazole) in one study had a statistically significant benefit on the SDS work/studies item. The study in question (Kamijima et al)<xref rid="b32-ndt-14-103" ref-type="bibr">32</xref> investigated two doses (3 mg and 3&#x02013;15 mg) of adjunctive aripiprazole in a 6-week randomized treatment phase, and both doses showed a benefit on the work/studies item. Three other studies of aripiprazole were included in the review; none of these showed efficacy on the SDS work/studies item, despite having almost identical designs to Kamijima et al.</p><p>On the SDS social life item, aripiprazole, brexpiprazole, edivoxetine, olanzapine (as OFC), and risperidone showed a benefit over placebo (<italic>p</italic>&#x0003c;0.05) in at least one study. On the SDS family life item, a benefit (<italic>p</italic>&#x0003c;0.05) was observed for aripiprazole, brexpiprazole, cariprazine, olanzapine (as OFC), and risperidone in at least one study.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>This review of 26 randomized placebo-controlled studies showed that, of the 13 adjunctive agents identified, only aripiprazole, brexpiprazole, edivoxetine, and risperidone statistically significantly improved functioning versus placebo, as measured by the SDS total or mean, in patients with MDD and inadequate response to at least one ADT. In a previous meta-analysis of adjunctive second-generation antipsychotics in MDD, which was conducted prior to the availability of brexpiprazole data, only aripiprazole and risperidone were found to provide a benefit based on a composite endpoint of patient-reported functioning and quality of life.<xref rid="b52-ndt-14-103" ref-type="bibr">52</xref> Furthermore, a systematic review in patients with MDD who received ADT (but no adjunctive pharmacotherapy) found that many patients, particularly partial responders, continued to experience functional impairments after treatment, highlighting an unmet need in MDD.<xref rid="b20-ndt-14-103" ref-type="bibr">20</xref></p><p>Other than edivoxetine, a selective norepinephrine reuptake inhibitor, the only agents to show statistically significant benefits on any SDS items in the present review were second-generation antipsychotics. Of these agents, aripiprazole and brexpiprazole have an indication for the adjunctive treatment of MDD, and OFC has an indication for the treatment of treatment-resistant depression (all in the US).<xref rid="b22-ndt-14-103" ref-type="bibr">22</xref>,<xref rid="b53-ndt-14-103" ref-type="bibr">53</xref>,<xref rid="b54-ndt-14-103" ref-type="bibr">54</xref> The development of edivoxetine as an adjunctive treatment for MDD was halted in 2013 because it failed to meet the primary endpoint in three Phase 3 studies.<xref rid="b55-ndt-14-103" ref-type="bibr">55</xref> Indeed, more than half of the adjunctive agents identified in this review failed to meet the primary efficacy endpoint of their respective studies. Nonetheless, the findings of this review suggest that the SDS as a whole is a useful scale to track changes in functioning among patients with inadequate response to ADTs, and that adjunctive second-generation antipsychotics or edivoxetine may improve functioning in such patients.</p><p>The SDS was the only self-rated measure of functional impairment that was used in the retrieved records. This observation is in line with a meta-analysis of second-generation antipsychotics for the adjunctive treatment of MDD.<xref rid="b52-ndt-14-103" ref-type="bibr">52</xref> Indeed, the SDS appears to be the most widely used functioning measure in studies of MDD.<xref rid="b20-ndt-14-103" ref-type="bibr">20</xref> The SDS is considered to be a reliable and valid measure of functioning impairment, originally developed in 1981 for use in treatment outcome studies in psychiatry.<xref rid="b49-ndt-14-103" ref-type="bibr">49</xref>&#x02013;<xref rid="b51-ndt-14-103" ref-type="bibr">51</xref> To the authors&#x02019; knowledge, no minimal clinically important difference has been established for the SDS. Sheehan selected the three items of work/studies, social life, and family life after reviewing other impairment instruments and consulting with patients and colleagues.<xref rid="b51-ndt-14-103" ref-type="bibr">51</xref> In general, all three items, including the work/studies item, are sensitive to treatment effects across a variety of psychological disorders.<xref rid="b51-ndt-14-103" ref-type="bibr">51</xref> In the present review, however, in the population of patients with MDD and inadequate response to ADTs, only aripiprazole had a statistically significant benefit on the SDS work/studies item, and this was only in one study out of four. Thus, where a benefit was observed on the SDS total or mean, this was generally driven by improvement on the social life and family life items.</p><p>There are several possible reasons for a lack of effect on the work/studies item in this population. Since the work/studies item is not rated for patients who are not working, one possibility is that the studies were underpowered to measure this item. In general, as shown in a US nationwide survey of patients with MDD, inadequate responders to ADT (based on self-reports) are less likely to be employed than responders.<xref rid="b14-ndt-14-103" ref-type="bibr">14</xref> Unfortunately, the majority of studies in the present review did not separate out the number of patients who rated each item of the SDS. Where such data were available, 10%&#x02013;35% of patients across the studies with a rating on the social life and family life items did not rate the work/studies item. Thus, the power to show a difference between treatment groups was reduced for the work/studies item compared with the other items.</p><p>Nevertheless, 65%&#x02013;90% of patients did rate the work/studies item, and therefore were in employment or studying. In general, studies have shown that people with depression who are in employment are less severely ill than those who are unemployed.<xref rid="b56-ndt-14-103" ref-type="bibr">56</xref>,<xref rid="b57-ndt-14-103" ref-type="bibr">57</xref> Thus, on average, the subset of patients who rated the work/studies item may be less severely ill than the total population in each study. Meta-analyses have investigated the question of whether or not antidepressant efficacy increases with baseline illness severity, with varying results.<xref rid="b58-ndt-14-103" ref-type="bibr">58</xref>,<xref rid="b59-ndt-14-103" ref-type="bibr">59</xref> If, as some have suggested, antidepressants are more efficacious in more severely ill patients, then the drug&#x02013;placebo difference may be expected to be greater in the total population (ie, on the social life and family life items) than in the subset of patients in employment (ie, on the work/studies item).</p><p>Finally, it is possible that the studies were too short to show a benefit on the work/studies item. With a few exceptions, the included studies assessed functioning after 6 or 8 weeks of adjunctive treatment. In general, job performance deficits can still remain after 18 months among patients whose depressive symptoms have improved,<xref rid="b60-ndt-14-103" ref-type="bibr">60</xref> and patients with inadequate response to ADT are particularly at risk of persisting impairment.<xref rid="b61-ndt-14-103" ref-type="bibr">61</xref> Thus, acute studies may not be able to detect a benefit in occupational functioning in this population of inadequate responders. Only one of the included studies was a long-term study, and, over 52 weeks, adjunctive dexmecamylamine did not show a notable difference to adjunctive placebo on the SDS total.<xref rid="b41-ndt-14-103" ref-type="bibr">41</xref> However, dexmecamylamine failed as an adjunctive agent in MDD, having shown no differences to placebo on the primary efficacy outcome in four acute studies,<xref rid="b39-ndt-14-103" ref-type="bibr">39</xref>,<xref rid="b40-ndt-14-103" ref-type="bibr">40</xref> and thus no benefit on the SDS might be expected.</p><p>Recent literature has acknowledged the difficulty in using the work/studies item among populations with a high proportion of non-workers, and attempts have been made to modify the SDS accordingly. Sonne et al proposed a rewording of the first item from &#x0201c;work/studies&#x0201d; to &#x0201c;work/daily tasks&#x0201d;, so that patients without a job could still rate the item.<xref rid="b62-ndt-14-103" ref-type="bibr">62</xref> Similarly, Bech reported a modified version of the SDS in which the work/studies item was replaced by an overall rating, &#x0201c;Your daily activities all things considered&#x0201d;.<xref rid="b63-ndt-14-103" ref-type="bibr">63</xref></p><p>The present review is limited because it only considered published literature, leading to a risk of publication bias (as positive studies are more likely to be published than failed or negative studies). However, even with the risk of publication bias, fewer than a third of the included studies reported a treatment benefit on the SDS. In addition, the review is limited since MEDLINE (via PubMed) was the only database searched. Nonetheless, the 26 studies identified had a consistent message, that the work/studies item is less informative in this population than the other two items.</p></sec><sec><title>Conclusion</title><p>The SDS, a self-rated functional measure, is informative in acute randomized placebo-controlled studies of adjunctive therapy in patients with MDD and inadequate response to ADT. However, the item that measures work performance may be less relevant to this population than the items that measure social and family life.</p></sec></body><back><ack><title>Acknowledgments</title><p>This review was funded by Otsuka Pharmaceutical Development &#x00026; Commercialization Inc. (Princeton, NJ, USA) and H. Lundbeck A/S (Valby, Denmark). Dr Jenny AR Muiry of Cambridge Medical Communication Ltd (Cambridge, UK) assisted with data collection. Cambridge Medical Communication Ltd also provided editorial support.</p></ack><fn-group><fn><p><bold>Author contributions</bold></p><p>CPW and CE performed data collection and analysis. All authors contributed toward data analysis, drafting and revising the paper, and agree to be accountable for all aspects of the work.</p></fn><fn fn-type="COI-statement"><p><bold>Disclosure</bold></p><p>EW and HE are employees of H. Lundbeck A/S. CW and MH are employees of Otsuka Pharmaceutical Development &#x00026; Commercialization Inc. CPW and CE are employees of Cambridge Medical Communication Ltd, which received funding from Otsuka Pharmaceutical Development &#x00026; Commercialization Inc. and H. Lundbeck A/S for this work. MF has received research support from, and has been a consultant or advisory board member for, all major pharmaceutical companies with drugs used in MDD. He owns the copyright for the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (ATRQ) and a number of other psychiatric rating scales. Full lifetime disclosures can be viewed online at: <ext-link ext-link-type="uri" xlink:href="http://mghcme.org/faculty/faculty-detail/maurizio_fava">http://mghcme.org/faculty/faculty-detail/maurizio_fava</ext-link>. He received no remuneration for his involvement in this review. The authors report no other conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-ndt-14-103"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>American Psychiatric Association</collab></person-group><source>Diagnostic and Statistical Manual of Mental Disorders</source><edition>5th ed</edition><publisher-loc>Arlington, VA</publisher-loc><publisher-name>American Psychiatric Association</publisher-name><year>2013</year></element-citation></ref><ref id="b2-ndt-14-103"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kessler</surname><given-names>RC</given-names></name></person-group><article-title>The costs of depression</article-title><source>Psychiatr Clin North Am</source><year>2012</year><volume>35</volume><issue>1</issue><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">22370487</pub-id></element-citation></ref><ref id="b3-ndt-14-103"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Druss</surname><given-names>BG</given-names></name><name><surname>Hwang</surname><given-names>I</given-names></name><name><surname>Petukhova</surname><given-names>M</given-names></name><name><surname>Sampson</surname><given-names>NA</given-names></name><name><surname>Wang</surname><given-names>PS</given-names></name><name><surname>Kessler</surname><given-names>RC</given-names></name></person-group><article-title>Impairment in role functioning in mental and chronic medical disorders in the United States: results from the National Comorbidity Survey Replication</article-title><source>Mol Psychiatry</source><year>2009</year><volume>14</volume><issue>7</issue><fpage>728</fpage><lpage>737</lpage><pub-id pub-id-type="pmid">18283278</pub-id></element-citation></ref><ref id="b4-ndt-14-103"><label>4</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>National Institute for Health and Clinical Excellence</collab></person-group><source>The NICE Guideline on the Treatment and Management of Depression in Adults</source><comment>(Updated Edition). NICE</comment><year>2010</year><comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://www.nice.org.uk/guidance/cg90/evidence/full-guidance-243833293">https://www.nice.org.uk/guidance/cg90/evidence/full-guidance-243833293</ext-link></comment><date-in-citation>Accessed November 16, 2017</date-in-citation></element-citation></ref><ref id="b5-ndt-14-103"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nierenberg</surname><given-names>AA</given-names></name><name><surname>DeCecco</surname><given-names>LM</given-names></name></person-group><article-title>Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression</article-title><source>J Clin Psychiatry</source><year>2001</year><volume>62</volume><issue>Suppl 16</issue><fpage>5</fpage><lpage>9</lpage></element-citation></ref><ref id="b6-ndt-14-103"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angst</surname><given-names>J</given-names></name><name><surname>Kupfer</surname><given-names>DJ</given-names></name><name><surname>Rosenbaum</surname><given-names>JF</given-names></name></person-group><article-title>Recovery from depression: risk or reality?</article-title><source>Acta Psychiatr Scand</source><year>1996</year><volume>93</volume><issue>6</issue><fpage>413</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">8831856</pub-id></element-citation></ref><ref id="b7-ndt-14-103"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fava</surname><given-names>GA</given-names></name><name><surname>Bech</surname><given-names>P</given-names></name></person-group><article-title>The concept of euthymia</article-title><source>Psychother Psychosom</source><year>2016</year><volume>85</volume><issue>1</issue><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">26610048</pub-id></element-citation></ref><ref id="b8-ndt-14-103"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimmerman</surname><given-names>M</given-names></name><name><surname>McGlinchey</surname><given-names>JB</given-names></name><name><surname>Posternak</surname><given-names>MA</given-names></name><name><surname>Friedman</surname><given-names>M</given-names></name><name><surname>Attiullah</surname><given-names>N</given-names></name><name><surname>Boerescu</surname><given-names>D</given-names></name></person-group><article-title>How should remission from depression be defined? The depressed patient&#x02019;s perspective</article-title><source>Am J Psychiatry</source><year>2006</year><volume>163</volume><issue>1</issue><fpage>148</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">16390903</pub-id></element-citation></ref><ref id="b9-ndt-14-103"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>VC</given-names></name><name><surname>Lam</surname><given-names>RW</given-names></name></person-group><article-title>Assessments of functional improvement: self-versus clinician-ratings</article-title><source>Medicographia</source><year>2014</year><volume>36</volume><issue>4</issue><fpage>512</fpage><lpage>520</lpage></element-citation></ref><ref id="b10-ndt-14-103"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saltiel</surname><given-names>PF</given-names></name><name><surname>Silvershein</surname><given-names>DI</given-names></name></person-group><article-title>Major depressive disorder: mechanism-based prescribing for personalized medicine</article-title><source>Neuropsychiatr Dis Treat</source><year>2015</year><volume>11</volume><fpage>875</fpage><lpage>888</lpage><pub-id pub-id-type="pmid">25848287</pub-id></element-citation></ref><ref id="b11-ndt-14-103"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKnight</surname><given-names>PE</given-names></name><name><surname>Kashdan</surname><given-names>TB</given-names></name></person-group><article-title>The importance of functional impairment to mental health outcomes: a case for reassessing our goals in depression treatment research</article-title><source>Clin Psychol Rev</source><year>2009</year><volume>29</volume><issue>3</issue><fpage>243</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">19269076</pub-id></element-citation></ref><ref id="b12-ndt-14-103"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rush</surname><given-names>AJ</given-names></name><name><surname>Trivedi</surname><given-names>MH</given-names></name><name><surname>Wisniewski</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report</article-title><source>Am J Psychiatry</source><year>2006</year><volume>163</volume><issue>11</issue><fpage>1905</fpage><lpage>1917</lpage><pub-id pub-id-type="pmid">17074942</pub-id></element-citation></ref><ref id="b13-ndt-14-103"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mauskopf</surname><given-names>JA</given-names></name><name><surname>Simon</surname><given-names>GE</given-names></name><name><surname>Kalsekar</surname><given-names>A</given-names></name><name><surname>Nimsch</surname><given-names>C</given-names></name><name><surname>Dunayevich</surname><given-names>E</given-names></name><name><surname>Cameron</surname><given-names>A</given-names></name></person-group><article-title>Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder</article-title><source>Depress Anxiety</source><year>2009</year><volume>26</volume><issue>1</issue><fpage>83</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">18833573</pub-id></element-citation></ref><ref id="b14-ndt-14-103"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knoth</surname><given-names>RL</given-names></name><name><surname>Bolge</surname><given-names>SC</given-names></name><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Tran</surname><given-names>QV</given-names></name></person-group><article-title>Effect of inadequate response to treatment in patients with depression</article-title><source>Am J Manag Care</source><year>2010</year><volume>16</volume><issue>8</issue><fpage>e188</fpage><lpage>e196</lpage><pub-id pub-id-type="pmid">20690785</pub-id></element-citation></ref><ref id="b15-ndt-14-103"><label>15</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>American Psychiatric Association</collab></person-group><source>Practice Guideline for the Treatment of Patients with Major Depressive Disorder</source><edition>3rd ed</edition><publisher-name>American Psychiatric Association</publisher-name><year>2010</year><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf">http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf</ext-link></comment><date-in-citation>Accessed November 16, 2017</date-in-citation></element-citation></ref><ref id="b16-ndt-14-103"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>SH</given-names></name><name><surname>Lam</surname><given-names>RW</given-names></name><name><surname>McIntyre</surname><given-names>RS</given-names></name><etal/></person-group><article-title>Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 3. Pharmacological treatments</article-title><source>Can J Psychiatry</source><year>2016</year><volume>61</volume><issue>9</issue><fpage>540</fpage><lpage>560</lpage><pub-id pub-id-type="pmid">27486148</pub-id></element-citation></ref><ref id="b17-ndt-14-103"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fava</surname><given-names>M</given-names></name></person-group><article-title>Pharmacological approaches to the treatment of residual symptoms</article-title><source>J Psychopharmacol</source><year>2006</year><volume>20</volume><issue>3 Suppl</issue><fpage>29</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">16644769</pub-id></element-citation></ref><ref id="b18-ndt-14-103"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fava</surname><given-names>M</given-names></name><name><surname>Rush</surname><given-names>AJ</given-names></name></person-group><article-title>Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice</article-title><source>Psychother Psychosom</source><year>2006</year><volume>75</volume><issue>3</issue><fpage>139</fpage><lpage>153</lpage><pub-id pub-id-type="pmid">16636629</pub-id></element-citation></ref><ref id="b19-ndt-14-103"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Connolly</surname><given-names>KR</given-names></name><name><surname>Thase</surname><given-names>ME</given-names></name></person-group><article-title>If at first you don&#x02019;t succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies</article-title><source>Drugs</source><year>2011</year><volume>71</volume><issue>1</issue><fpage>43</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">21175239</pub-id></element-citation></ref><ref id="b20-ndt-14-103"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheehan</surname><given-names>DV</given-names></name><name><surname>Nakagome</surname><given-names>K</given-names></name><name><surname>Asami</surname><given-names>Y</given-names></name><name><surname>Pappadopulos</surname><given-names>EA</given-names></name><name><surname>Boucher</surname><given-names>M</given-names></name></person-group><article-title>Restoring function in major depressive disorder: a systematic review</article-title><source>J Affect Disord</source><year>2017</year><volume>215</volume><fpage>299</fpage><lpage>313</lpage><pub-id pub-id-type="pmid">28364701</pub-id></element-citation></ref><ref id="b21-ndt-14-103"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liberati</surname><given-names>A</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Tetzlaff</surname><given-names>J</given-names></name><etal/></person-group><article-title>The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration</article-title><source>PLoS Med</source><year>2009</year><volume>6</volume><issue>7</issue><fpage>e1000100</fpage><pub-id pub-id-type="pmid">19621070</pub-id></element-citation></ref><ref id="b22-ndt-14-103"><label>22</label><element-citation publication-type="book"><source>Symbyax<sup>&#x000ae;</sup> (olanzapine and fluoxetine) capsules for oral use [prescribing information]</source><publisher-loc>Indianapolis, IN</publisher-loc><publisher-name>Lilly USA, LLC</publisher-name><year>2017</year></element-citation></ref><ref id="b23-ndt-14-103"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thase</surname><given-names>ME</given-names></name><name><surname>Trivedi</surname><given-names>MH</given-names></name><name><surname>Nelson</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies</article-title><source>Prim Care Companion J Clin Psychiatry</source><year>2008</year><volume>10</volume><issue>6</issue><fpage>440</fpage><lpage>447</lpage><pub-id pub-id-type="pmid">19287552</pub-id></element-citation></ref><ref id="b24-ndt-14-103"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trivedi</surname><given-names>MH</given-names></name><name><surname>Corey-Lisle</surname><given-names>PK</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Lennox</surname><given-names>RD</given-names></name><name><surname>Pikalov</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>E</given-names></name></person-group><article-title>Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning</article-title><source>Int Clin Psychopharmacol</source><year>2009</year><volume>24</volume><issue>3</issue><fpage>133</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">19318972</pub-id></element-citation></ref><ref id="b25-ndt-14-103"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steffens</surname><given-names>DC</given-names></name><name><surname>Nelson</surname><given-names>JC</given-names></name><name><surname>Eudicone</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis</article-title><source>Int J Geriatr Psychiatry</source><year>2011</year><volume>26</volume><issue>6</issue><fpage>564</fpage><lpage>572</lpage><pub-id pub-id-type="pmid">20827794</pub-id></element-citation></ref><ref id="b26-ndt-14-103"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fabian</surname><given-names>TJ</given-names></name><name><surname>Cain</surname><given-names>ZJ</given-names></name><name><surname>Ammerman</surname><given-names>D</given-names></name><etal/></person-group><article-title>Improvement in functional outcomes with adjunctive aripiprazole versus placebo in major depressive disorder: a pooled post hoc analysis of 3 short-term studies</article-title><source>Prim Care Companion CNS Disord</source><year>2012</year><volume>14</volume><issue>6</issue></element-citation></ref><ref id="b27-ndt-14-103"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>JC</given-names></name><name><surname>Rahman</surname><given-names>Z</given-names></name><name><surname>Laubmeier</surname><given-names>KK</given-names></name><etal/></person-group><article-title>Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy</article-title><source>CNS Spectr</source><year>2014</year><volume>19</volume><issue>6</issue><fpage>528</fpage><lpage>534</lpage><pub-id pub-id-type="pmid">24642260</pub-id></element-citation></ref><ref id="b28-ndt-14-103"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandina</surname><given-names>GJ</given-names></name><name><surname>Revicki</surname><given-names>DA</given-names></name><name><surname>Kleinman</surname><given-names>L</given-names></name><etal/></person-group><article-title>Patient-rated troubling symptoms of depression instrument results correlate with traditional clinician-and patient-rated measures: a secondary analysis of a randomized, double-blind, placebo-controlled trial</article-title><source>J Affect Disord</source><year>2009</year><volume>118</volume><issue>1&#x02013;3</issue><fpage>139</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">19321206</pub-id></element-citation></ref><ref id="b29-ndt-14-103"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berman</surname><given-names>RM</given-names></name><name><surname>Marcus</surname><given-names>RN</given-names></name><name><surname>Swanink</surname><given-names>R</given-names></name><name><surname>McQuade</surname><given-names>RD</given-names></name><name><surname>Carson</surname><given-names>WH</given-names></name><name><surname>Corey-Lisle</surname><given-names>PK</given-names></name><name><surname>Khan</surname><given-names>A</given-names></name></person-group><article-title>The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study</article-title><source>J Clin Psychiatry</source><year>2007</year><volume>68</volume><issue>6</issue><fpage>843</fpage><lpage>853</lpage><pub-id pub-id-type="pmid">17592907</pub-id></element-citation></ref><ref id="b30-ndt-14-103"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcus</surname><given-names>RN</given-names></name><name><surname>McQuade</surname><given-names>RD</given-names></name><name><surname>Carson</surname><given-names>WH</given-names></name><etal/></person-group><article-title>The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study</article-title><source>J Clin Psychopharmacol</source><year>2008</year><volume>28</volume><issue>2</issue><fpage>156</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">18344725</pub-id></element-citation></ref><ref id="b31-ndt-14-103"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berman</surname><given-names>RM</given-names></name><name><surname>Fava</surname><given-names>M</given-names></name><name><surname>Thase</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants</article-title><source>CNS Spectr</source><year>2009</year><volume>14</volume><issue>4</issue><fpage>197</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">19407731</pub-id></element-citation></ref><ref id="b32-ndt-14-103"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamijima</surname><given-names>K</given-names></name><name><surname>Higuchi</surname><given-names>T</given-names></name><name><surname>Ishigooka</surname><given-names>J</given-names></name><etal/></person-group><article-title>Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study)</article-title><source>J Affect Disord</source><year>2013</year><volume>151</volume><issue>3</issue><fpage>899</fpage><lpage>905</lpage><pub-id pub-id-type="pmid">24074484</pub-id></element-citation></ref><ref id="b33-ndt-14-103"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quiroz</surname><given-names>JA</given-names></name><name><surname>Tamburri</surname><given-names>P</given-names></name><name><surname>Deptula</surname><given-names>D</given-names></name><etal/></person-group><article-title>Efficacy and safety of basimglurant as adjunctive therapy for major depression: a randomized clinical trial</article-title><source>JAMA Psychiatry</source><year>2016</year><volume>73</volume><issue>7</issue><fpage>675</fpage><lpage>684</lpage><pub-id pub-id-type="pmid">27304433</pub-id></element-citation></ref><ref id="b34-ndt-14-103"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thase</surname><given-names>ME</given-names></name><name><surname>Youakim</surname><given-names>JM</given-names></name><name><surname>Skuban</surname><given-names>A</given-names></name><etal/></person-group><article-title>Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a Phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants</article-title><source>J Clin Psychiatry</source><year>2015</year><volume>76</volume><issue>9</issue><fpage>1224</fpage><lpage>1231</lpage><pub-id pub-id-type="pmid">26301701</pub-id></element-citation></ref><ref id="b35-ndt-14-103"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thase</surname><given-names>ME</given-names></name><name><surname>Youakim</surname><given-names>JM</given-names></name><name><surname>Skuban</surname><given-names>A</given-names></name><etal/></person-group><article-title>Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a Phase 3, randomized, double-blind study</article-title><source>J Clin Psychiatry</source><year>2015</year><volume>76</volume><issue>9</issue><fpage>1232</fpage><lpage>1240</lpage><pub-id pub-id-type="pmid">26301771</pub-id></element-citation></ref><ref id="b36-ndt-14-103"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fava</surname><given-names>M</given-names></name><name><surname>Memisoglu</surname><given-names>A</given-names></name><name><surname>Thase</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Opioid modulation with buprenorphine/samidorphan as adjunctive treatment for inadequate response to antidepressants: a randomized double-blind placebo-controlled trial</article-title><source>Am J Psychiatry</source><year>2016</year><volume>173</volume><issue>5</issue><fpage>499</fpage><lpage>508</lpage><pub-id pub-id-type="pmid">26869247</pub-id></element-citation></ref><ref id="b37-ndt-14-103"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durgam</surname><given-names>S</given-names></name><name><surname>Earley</surname><given-names>W</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><etal/></person-group><article-title>Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder</article-title><source>J Clin Psychiatry</source><year>2016</year><volume>77</volume><issue>3</issue><fpage>371</fpage><lpage>378</lpage><pub-id pub-id-type="pmid">27046309</pub-id></element-citation></ref><ref id="b38-ndt-14-103"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fava</surname><given-names>M</given-names></name><name><surname>Ramey</surname><given-names>T</given-names></name><name><surname>Pickering</surname><given-names>E</given-names></name><name><surname>Kinrys</surname><given-names>G</given-names></name><name><surname>Boyer</surname><given-names>S</given-names></name><name><surname>Altstiel</surname><given-names>L</given-names></name></person-group><article-title>A randomized, double-blind, placebo-controlled Phase 2 study of the augmentation of a nicotinic acetylcholine receptor partial agonist in depression: is there a relationship to leptin levels?</article-title><source>J Clin Psychopharmacol</source><year>2015</year><volume>35</volume><issue>1</issue><fpage>51</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">25422883</pub-id></element-citation></ref><ref id="b39-ndt-14-103"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vieta</surname><given-names>E</given-names></name><name><surname>Thase</surname><given-names>ME</given-names></name><name><surname>Naber</surname><given-names>D</given-names></name><etal/></person-group><article-title>Efficacy and tolerability of flexibly-dosed adjunct TC-5214 (dexmecamylamine) in patients with major depressive disorder and inadequate response to prior antidepressant</article-title><source>Eur Neuropsychopharmacol</source><year>2014</year><volume>24</volume><issue>4</issue><fpage>564</fpage><lpage>574</lpage><pub-id pub-id-type="pmid">24507016</pub-id></element-citation></ref><ref id="b40-ndt-14-103"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000f6;ller</surname><given-names>HJ</given-names></name><name><surname>Demyttenaere</surname><given-names>K</given-names></name><name><surname>Olausson</surname><given-names>B</given-names></name><etal/></person-group><article-title>Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy</article-title><source>World J Biol Psychiatry</source><year>2015</year><volume>16</volume><issue>7</issue><fpage>483</fpage><lpage>501</lpage><pub-id pub-id-type="pmid">25602163</pub-id></element-citation></ref><ref id="b41-ndt-14-103"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tummala</surname><given-names>R</given-names></name><name><surname>Desai</surname><given-names>D</given-names></name><name><surname>Szamosi</surname><given-names>J</given-names></name><name><surname>Wilson</surname><given-names>E</given-names></name><name><surname>Hosford</surname><given-names>D</given-names></name><name><surname>Dunbar</surname><given-names>G</given-names></name><name><surname>Eriksson</surname><given-names>H</given-names></name></person-group><article-title>Safety and tolerability of dexmecamylamine (TC-5214) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to antidepressant therapy: results of a long-term study</article-title><source>J Clin Psychopharmacol</source><year>2015</year><volume>35</volume><issue>1</issue><fpage>77</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">25514064</pub-id></element-citation></ref><ref id="b42-ndt-14-103"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ball</surname><given-names>S</given-names></name><name><surname>Dellva</surname><given-names>MA</given-names></name><name><surname>D&#x02019;Souza</surname><given-names>DN</given-names></name><name><surname>Marangell</surname><given-names>LB</given-names></name><name><surname>Russell</surname><given-names>JM</given-names></name><name><surname>Goldberger</surname><given-names>C</given-names></name></person-group><article-title>A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment</article-title><source>J Affect Disord</source><year>2014</year><volume>167</volume><fpage>215</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">24995890</pub-id></element-citation></ref><ref id="b43-ndt-14-103"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ball</surname><given-names>SG</given-names></name><name><surname>Ferguson</surname><given-names>MB</given-names></name><name><surname>Martinez</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Efficacy outcomes from 3 clinical trials of edivoxetine as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment</article-title><source>J Clin Psychiatry</source><year>2016</year><volume>77</volume><issue>5</issue><fpage>635</fpage><lpage>642</lpage><pub-id pub-id-type="pmid">27035159</pub-id></element-citation></ref><ref id="b44-ndt-14-103"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbee</surname><given-names>JG</given-names></name><name><surname>Thompson</surname><given-names>TR</given-names></name><name><surname>Jamhour</surname><given-names>NJ</given-names></name><etal/></person-group><article-title>A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression</article-title><source>J Clin Psychiatry</source><year>2011</year><volume>72</volume><issue>10</issue><fpage>1405</fpage><lpage>1412</lpage><pub-id pub-id-type="pmid">21367355</pub-id></element-citation></ref><ref id="b45-ndt-14-103"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanacora</surname><given-names>G</given-names></name><name><surname>Johnson</surname><given-names>MR</given-names></name><name><surname>Khan</surname><given-names>A</given-names></name><etal/></person-group><article-title>Adjunctive lanicemine (AZD6765) in patients with major depressive disorder and history of inadequate response to antidepressants: a randomized, placebo-controlled study</article-title><source>Neuropsychopharmacology</source><year>2017</year><volume>42</volume><issue>4</issue><fpage>844</fpage><lpage>853</lpage><pub-id pub-id-type="pmid">27681442</pub-id></element-citation></ref><ref id="b46-ndt-14-103"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richards</surname><given-names>C</given-names></name><name><surname>McIntyre</surname><given-names>RS</given-names></name><name><surname>Weisler</surname><given-names>R</given-names></name><etal/></person-group><article-title>Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: results from 2 Phase 3, multicenter, randomized, double-blind, placebo-controlled studies</article-title><source>J Affect Disord</source><year>2016</year><volume>206</volume><fpage>151</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">27474961</pub-id></element-citation></ref><ref id="b47-ndt-14-103"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thase</surname><given-names>ME</given-names></name><name><surname>Corya</surname><given-names>SA</given-names></name><name><surname>Osuntokun</surname><given-names>O</given-names></name><etal/></person-group><article-title>A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder</article-title><source>J Clin Psychiatry</source><year>2007</year><volume>68</volume><issue>2</issue><fpage>224</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">17335320</pub-id></element-citation></ref><ref id="b48-ndt-14-103"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahmoud</surname><given-names>RA</given-names></name><name><surname>Pandina</surname><given-names>GJ</given-names></name><name><surname>Turkoz</surname><given-names>I</given-names></name><name><surname>Kosik-Gonzalez</surname><given-names>C</given-names></name><name><surname>Canuso</surname><given-names>CM</given-names></name><name><surname>Kujawa</surname><given-names>MJ</given-names></name><name><surname>Gharabawi-Garibaldi</surname><given-names>GM</given-names></name></person-group><article-title>Risperidone for treatment-refractory major depressive disorder: a randomized trial</article-title><source>Ann Intern Med</source><year>2007</year><volume>147</volume><issue>9</issue><fpage>593</fpage><lpage>602</lpage><pub-id pub-id-type="pmid">17975181</pub-id></element-citation></ref><ref id="b49-ndt-14-103"><label>49</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Sheehan</surname><given-names>DV</given-names></name></person-group><source>The Anxiety Disease</source><publisher-loc>New York</publisher-loc><publisher-name>Charles Scribner &#x00026; Sons</publisher-name><year>1983</year></element-citation></ref><ref id="b50-ndt-14-103"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheehan</surname><given-names>DV</given-names></name><name><surname>Harnett-Sheehan</surname><given-names>K</given-names></name><name><surname>Raj</surname><given-names>BA</given-names></name></person-group><article-title>The measurement of disability</article-title><source>Int Clin Psychopharmacol</source><year>1996</year><volume>11</volume><issue>Suppl 3</issue><fpage>89</fpage><lpage>95</lpage></element-citation></ref><ref id="b51-ndt-14-103"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheehan</surname><given-names>KH</given-names></name><name><surname>Sheehan</surname><given-names>DV</given-names></name></person-group><article-title>Assessing treatment effects in clinical trials with the Discan metric of the Sheehan Disability Scale</article-title><source>Int Clin Psychopharmacol</source><year>2008</year><volume>23</volume><issue>2</issue><fpage>70</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">18301121</pub-id></element-citation></ref><ref id="b52-ndt-14-103"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spielmans</surname><given-names>GI</given-names></name><name><surname>Berman</surname><given-names>MI</given-names></name><name><surname>Linardatos</surname><given-names>E</given-names></name><name><surname>Rosenlicht</surname><given-names>NZ</given-names></name><name><surname>Perry</surname><given-names>A</given-names></name><name><surname>Tsai</surname><given-names>AC</given-names></name></person-group><article-title>Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes</article-title><source>PLoS Med</source><year>2013</year><volume>10</volume><issue>3</issue><fpage>e1001403</fpage><pub-id pub-id-type="pmid">23554581</pub-id></element-citation></ref><ref id="b53-ndt-14-103"><label>53</label><element-citation publication-type="book"><source>Abilify<sup>&#x000ae;</sup> (aripiprazole) tablets; Abilify Discmelt<sup>&#x000ae;</sup> (aripiprazole) orally disintegrating tablets; Abilify<sup>&#x000ae;</sup> (aripiprazole) oral solution; Abilify<sup>&#x000ae;</sup> (aripiprazole) injection for intramuscular use only [prescribing information]</source><publisher-loc>Tokyo, Japan</publisher-loc><publisher-name>Otsuka Pharmaceutical Co., Ltd.</publisher-name><year>2017</year></element-citation></ref><ref id="b54-ndt-14-103"><label>54</label><element-citation publication-type="book"><source>Rexulti<sup>&#x000ae;</sup> (brexpiprazole) tablets, for oral use [prescribing information]</source><publisher-loc>Tokyo, Japan</publisher-loc><publisher-name>Otsuka Pharmaceutical Co., Ltd.</publisher-name><year>2017</year></element-citation></ref><ref id="b55-ndt-14-103"><label>55</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Eli Lilly and Company</collab></person-group><source>Lilly announces edivoxetine did not meet primary endpoint of Phase III clinical studies as add-on therapy for major depressive disorder [press release]</source><publisher-loc>Indianapolis, IN</publisher-loc><publisher-name>Eli Lilly and Company</publisher-name><fpage>2013</fpage><comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://investor.lilly.com/releasedetail.cfm?ReleaseID=811751">https://investor.lilly.com/releasedetail.cfm?ReleaseID=811751</ext-link></comment><date-in-citation>Accessed November 17, 2017</date-in-citation></element-citation></ref><ref id="b56-ndt-14-103"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>A</given-names></name><name><surname>Crain</surname><given-names>AL</given-names></name><name><surname>Solberg</surname><given-names>LI</given-names></name><name><surname>Un&#x000fc;tzer</surname><given-names>J</given-names></name><name><surname>Glasgow</surname><given-names>RE</given-names></name><name><surname>Maciosek</surname><given-names>MV</given-names></name><name><surname>Whitebird</surname><given-names>R</given-names></name></person-group><article-title>Severity of depression and magnitude of productivity loss</article-title><source>Ann Fam Med</source><year>2011</year><volume>9</volume><issue>4</issue><fpage>305</fpage><lpage>311</lpage><pub-id pub-id-type="pmid">21747101</pub-id></element-citation></ref><ref id="b57-ndt-14-103"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiles</surname><given-names>NJ</given-names></name><name><surname>Mulligan</surname><given-names>J</given-names></name><name><surname>Peters</surname><given-names>TJ</given-names></name><etal/></person-group><article-title>Severity of depression and response to antidepressants: GENPOD randomised controlled trial</article-title><source>Br J Psychiatry</source><year>2012</year><volume>200</volume><issue>2</issue><fpage>130</fpage><lpage>136</lpage><pub-id pub-id-type="pmid">22194183</pub-id></element-citation></ref><ref id="b58-ndt-14-103"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirsch</surname><given-names>I</given-names></name><name><surname>Deacon</surname><given-names>BJ</given-names></name><name><surname>Huedo-Medina</surname><given-names>TB</given-names></name><name><surname>Scoboria</surname><given-names>A</given-names></name><name><surname>Moore</surname><given-names>TJ</given-names></name><name><surname>Johnson</surname><given-names>BT</given-names></name></person-group><article-title>Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration</article-title><source>PLoS Med</source><year>2008</year><volume>5</volume><issue>2</issue><fpage>e45</fpage><pub-id pub-id-type="pmid">18303940</pub-id></element-citation></ref><ref id="b59-ndt-14-103"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fountoulakis</surname><given-names>KN</given-names></name><name><surname>Veroniki</surname><given-names>AA</given-names></name><name><surname>Siamouli</surname><given-names>M</given-names></name><name><surname>M&#x000f6;ller</surname><given-names>HJ</given-names></name></person-group><article-title>No role for initial severity on the efficacy of antidepressants: results of a multi-meta-analysis</article-title><source>Ann Gen Psychiatry</source><year>2013</year><volume>12</volume><issue>1</issue><fpage>26</fpage><pub-id pub-id-type="pmid">23941527</pub-id></element-citation></ref><ref id="b60-ndt-14-103"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adler</surname><given-names>DA</given-names></name><name><surname>McLaughlin</surname><given-names>TJ</given-names></name><name><surname>Rogers</surname><given-names>WH</given-names></name><name><surname>Chang</surname><given-names>H</given-names></name><name><surname>Lapitsky</surname><given-names>L</given-names></name><name><surname>Lerner</surname><given-names>D</given-names></name></person-group><article-title>Job performance deficits due to depression</article-title><source>Am J Psychiatry</source><year>2006</year><volume>163</volume><issue>9</issue><fpage>1569</fpage><lpage>1576</lpage><pub-id pub-id-type="pmid">16946182</pub-id></element-citation></ref><ref id="b61-ndt-14-103"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trivedi</surname><given-names>MH</given-names></name><name><surname>Morris</surname><given-names>DW</given-names></name><name><surname>Wisniewski</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Increase in work productivity of depressed individuals with improvement in depressive symptom severity</article-title><source>Am J Psychiatry</source><year>2013</year><volume>170</volume><issue>6</issue><fpage>633</fpage><lpage>641</lpage><pub-id pub-id-type="pmid">23558394</pub-id></element-citation></ref><ref id="b62-ndt-14-103"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonne</surname><given-names>C</given-names></name><name><surname>Carlsson</surname><given-names>J</given-names></name><name><surname>Bech</surname><given-names>P</given-names></name><name><surname>Elklit</surname><given-names>A</given-names></name><name><surname>Mortensen</surname><given-names>EL</given-names></name></person-group><article-title>Treatment of trauma-affected refugees with venlafaxine versus sertraline combined with psychotherapy &#x02013; a randomised study</article-title><source>BMC Psychiatry</source><year>2016</year><volume>16</volume><issue>1</issue><fpage>383</fpage><pub-id pub-id-type="pmid">27825327</pub-id></element-citation></ref><ref id="b63-ndt-14-103"><label>63</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bech</surname><given-names>P</given-names></name></person-group><source>Measurement-Based Care in Mental Disorders</source><publisher-loc>Cham, Switzerland</publisher-loc><publisher-name>Springer International Publishing AG</publisher-name><year>2016</year></element-citation></ref></ref-list></back><floats-group><fig id="f1-ndt-14-103" position="float"><label>Figure 1</label><caption><p>Flow diagram of published articles examined for inclusion in a systematic review.</p><p><bold>Abbreviations:</bold> ADT, antidepressant treatment; MDD, major depressive disorder; OFC, olanzapine&#x02013;fluoxetine combination.</p></caption><graphic xlink:href="ndt-14-103Fig1"/></fig><table-wrap id="t1-ndt-14-103" position="float"><label>Table 1</label><caption><p>Characteristics of included studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="top" align="left" colspan="1">Reference (ClinicalTrials.gov identifier)</th><th rowspan="2" valign="top" align="left" colspan="1">Adjunctive treatment</th><th rowspan="2" valign="top" align="left" colspan="1">Adjunctive treatment duration</th><th rowspan="2" valign="top" align="left" colspan="1">Randomized patients</th><th rowspan="2" valign="top" align="left" colspan="1">Inadequate response to (current episode)</th><th colspan="2" valign="top" align="left" rowspan="1">Inadequate response definition
<hr/></th><th rowspan="2" valign="top" align="left" colspan="1">Primary efficacy measure</th><th rowspan="2" valign="top" align="left" colspan="1">Setting</th><th rowspan="2" valign="top" align="left" colspan="1">Source of funding</th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Historical ADT<xref ref-type="table-fn" rid="tfn1-ndt-14-103">a</xref></th><th valign="top" align="left" rowspan="1" colspan="1">Prospective/ongoing ADT<xref ref-type="table-fn" rid="tfn2-ndt-14-103">b</xref></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Berman et al, 2007<xref rid="b29-ndt-14-103" ref-type="bibr">29</xref> (NCT00095823)</td><td valign="top" align="left" rowspan="1" colspan="1">Aripiprazole 2&#x02013;20 mg</td><td valign="top" align="left" rowspan="1" colspan="1">6 weeks</td><td valign="top" align="left" rowspan="1" colspan="1">362</td><td valign="top" align="left" rowspan="1" colspan="1">1&#x02013;3 historical ADTs + 1 prospective SSRI/SNRI</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;50% improved on ATRQ</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;50% reduction in HAM-D<sub>17</sub> total score from start of prospective treatment to week 8; HAM-D<sub>17</sub> total score &#x02265;14 and CGI-I score &#x02265;3 at week 8</td><td valign="top" align="left" rowspan="1" colspan="1">MADRS total</td><td valign="top" align="left" rowspan="1" colspan="1">24 outpatient sites in the US</td><td valign="top" align="left" rowspan="1" colspan="1">Bristol-Myers Squibb and Otsuka</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Marcus et al, 2008<xref rid="b30-ndt-14-103" ref-type="bibr">30</xref> (NCT00095758)</td><td valign="top" align="left" rowspan="1" colspan="1">Aripiprazole 2&#x02013;20 mg</td><td valign="top" align="left" rowspan="1" colspan="1">6 weeks</td><td valign="top" align="left" rowspan="1" colspan="1">381</td><td valign="top" align="left" rowspan="1" colspan="1">1&#x02013;3 historical ADTs + 1 prospective SSRI/SNRI</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;50% improved on ATRQ</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;50% reduction in HAM-D<sub>17</sub> total score from start of prospective treatment to week 8; HAM-D<sub>17</sub> total score &#x02265;14 and CGI-I score &#x02265;3 at week 8</td><td valign="top" align="left" rowspan="1" colspan="1">MADRS total</td><td valign="top" align="left" rowspan="1" colspan="1">36 outpatient sites in the US</td><td valign="top" align="left" rowspan="1" colspan="1">Bristol-Myers Squibb and Otsuka</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Berman et al, 2009<xref rid="b31-ndt-14-103" ref-type="bibr">31</xref> (NCT00105196)</td><td valign="top" align="left" rowspan="1" colspan="1">Aripiprazole 2&#x02013;20 mg</td><td valign="top" align="left" rowspan="1" colspan="1">6 weeks</td><td valign="top" align="left" rowspan="1" colspan="1">349</td><td valign="top" align="left" rowspan="1" colspan="1">1&#x02013;3 historical ADTs + 1 prospective SSRI/SNRI</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;50% improved on ATRQ</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;50% reduction in HAM-D<sub>17</sub> total score from start of prospective treatment to week 8; HAM-D<sub>17</sub> total score &#x02265;14 at week 8; CGI-I score &#x02265;3 at weeks 6 and 8</td><td valign="top" align="left" rowspan="1" colspan="1">MADRS total</td><td valign="top" align="left" rowspan="1" colspan="1">36 outpatient sites in the US</td><td valign="top" align="left" rowspan="1" colspan="1">Bristol-Myers Squibb and Otsuka</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Kamijima et al, 2013<xref rid="b32-ndt-14-103" ref-type="bibr">32</xref> (NCT00876343)</td><td valign="top" align="left" rowspan="1" colspan="1">Aripiprazole 3 mg/3&#x02013;15 mg</td><td valign="top" align="left" rowspan="1" colspan="1">6 weeks</td><td valign="top" align="left" rowspan="1" colspan="1">586</td><td valign="top" align="left" rowspan="1" colspan="1">1&#x02013;3 historical ADTs + 1 prospective ADT</td><td valign="top" align="left" rowspan="1" colspan="1">Not specified</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;50% reduction in HAM-D<sub>17</sub> total score from start of prospective treatment to week 8; HAM-D<sub>17</sub> total score &#x02265;14 and CGI-I score &#x02265;3 at week 8<xref ref-type="table-fn" rid="tfn3-ndt-14-103">c</xref></td><td valign="top" align="left" rowspan="1" colspan="1">MADRS total</td><td valign="top" align="left" rowspan="1" colspan="1">169 sites in Japan</td><td valign="top" align="left" rowspan="1" colspan="1">Otsuka</td></tr><tr><td colspan="10" valign="bottom" align="center" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Quiroz et al, 2016<xref rid="b33-ndt-14-103" ref-type="bibr">33</xref> (NCT01437657)</td><td valign="top" align="left" rowspan="1" colspan="1">Basimglurant MR 0.5 mg/1.5 mg</td><td valign="top" align="left" rowspan="1" colspan="1">6 weeks</td><td valign="top" align="left" rowspan="1" colspan="1">333</td><td valign="top" align="left" rowspan="1" colspan="1">1&#x02013;3 historical ADTs (1 ongoing SSRI/SNRI)</td><td valign="top" align="left" rowspan="1" colspan="1">Investigator judgment</td><td valign="top" align="left" rowspan="1" colspan="1">MADRS total score &#x02265;25 and CGI-S score &#x02265;4 at screening<xref ref-type="table-fn" rid="tfn4-ndt-14-103">d</xref></td><td valign="top" align="left" rowspan="1" colspan="1">MADRS total</td><td valign="top" align="left" rowspan="1" colspan="1">59 outpatient sites in Chile, Europe, Japan, Mexico, and the US</td><td valign="top" align="left" rowspan="1" colspan="1">Hoffmann-La Roche</td></tr><tr><td colspan="10" valign="bottom" align="center" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Thase et al, 2015<xref rid="b34-ndt-14-103" ref-type="bibr">34</xref> (NCT01360645)</td><td valign="top" align="left" rowspan="1" colspan="1">Brexpiprazole 2 mg</td><td valign="top" align="left" rowspan="1" colspan="1">6 weeks</td><td valign="top" align="left" rowspan="1" colspan="1">379</td><td valign="top" align="left" rowspan="1" colspan="1">1&#x02013;3 historical ADTs + 1 prospective SSRI/SNRI</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;50% improved on ATRQ</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;50% reduction in HAM-D<sub>17</sub> total score from start of prospective treatment to week 8; HAM-D<sub>17</sub> total score &#x02265;14 at week 8; &#x0003c;50% reduction in MADRS total score from start of prospective treatment to weeks 2, 4, 6, and 8; CGI-I score &#x02265;3 at weeks 2, 4, 6, and 8<xref ref-type="table-fn" rid="tfn5-ndt-14-103">e</xref></td><td valign="top" align="left" rowspan="1" colspan="1">MADRS total</td><td valign="top" align="left" rowspan="1" colspan="1">59 outpatient sites in Canada, Europe, and the US</td><td valign="top" align="left" rowspan="1" colspan="1">Otsuka and Lundbeck</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Thase et al, 2015<xref rid="b35-ndt-14-103" ref-type="bibr">35</xref> (NCT01360632)</td><td valign="top" align="left" rowspan="1" colspan="1">Brexpiprazole 1 mg/3 mg</td><td valign="top" align="left" rowspan="1" colspan="1">6 weeks</td><td valign="top" align="left" rowspan="1" colspan="1">677</td><td valign="top" align="left" rowspan="1" colspan="1">1&#x02013;3 historical ADTs + 1 prospective SSRI/SNRI</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;50% improved on ATRQ</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;50% reduction in HAM-D<sub>17</sub> total score from start of prospective treatment to week 8; HAM-D<sub>17</sub> total score &#x02265;14 at week 8; &#x0003c;50% reduction in MADRS total score from start of prospective treatment to weeks 2, 4, 6, and 8; CGI-I score &#x02265;3 at weeks 2, 4, 6, and 8<xref ref-type="table-fn" rid="tfn5-ndt-14-103">e</xref></td><td valign="top" align="left" rowspan="1" colspan="1">MADRS total</td><td valign="top" align="left" rowspan="1" colspan="1">92 outpatient sites in Canada, Europe, Russia, and the US</td><td valign="top" align="left" rowspan="1" colspan="1">Otsuka and Lundbeck</td></tr><tr><td colspan="10" valign="bottom" align="center" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Fava et al, 2016<xref rid="b36-ndt-14-103" ref-type="bibr">36</xref> (NCT01500200)</td><td valign="top" align="left" rowspan="1" colspan="1">Buprenorphine + samidorphan 2 mg + 2 mg/8 mg + 8 mg</td><td valign="top" align="left" rowspan="1" colspan="1">Stage 1: 5 weeks; stage 2: 5 weeks<xref ref-type="table-fn" rid="tfn6-ndt-14-103">f</xref></td><td valign="top" align="left" rowspan="1" colspan="1">142</td><td valign="top" align="left" rowspan="1" colspan="1">1&#x02013;2 historical ADTs (1 ongoing)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;50% improved on ATRQ</td><td valign="top" align="left" rowspan="1" colspan="1">For entry into stage 2<xref ref-type="table-fn" rid="tfn6-ndt-14-103">f</xref>: &#x0003c;50% reduction in HAM-D<sub>17</sub> total score from start of stage 1 to week 5; HAM-D<sub>17</sub> total score &#x02265;14 at week 5</td><td valign="top" align="left" rowspan="1" colspan="1">HAM-D<sub>17</sub> total</td><td valign="top" align="left" rowspan="1" colspan="1">31 sites in the US</td><td valign="top" align="left" rowspan="1" colspan="1">Alkermes</td></tr><tr><td colspan="10" valign="bottom" align="center" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Durgam et al, 2016<xref rid="b37-ndt-14-103" ref-type="bibr">37</xref> (NCT01469377)</td><td valign="top" align="left" rowspan="1" colspan="1">Cariprazine 1&#x02013;2 mg/2&#x02013;4.5 mg</td><td valign="top" align="left" rowspan="1" colspan="1">8 weeks</td><td valign="top" align="left" rowspan="1" colspan="1">819</td><td valign="top" align="left" rowspan="1" colspan="1">1&#x02013;2 historical ADTs (1 ongoing)</td><td valign="top" align="left" rowspan="1" colspan="1">Not specified</td><td valign="top" align="left" rowspan="1" colspan="1">ATHF resistance rating &#x02265;3 with global confidence &#x02265;3 at screening<xref ref-type="table-fn" rid="tfn5-ndt-14-103">e</xref></td><td valign="top" align="left" rowspan="1" colspan="1">MADRS total</td><td valign="top" align="left" rowspan="1" colspan="1">76 outpatient sites in Europe and the US</td><td valign="top" align="left" rowspan="1" colspan="1">Forest Laboratories (Allergan) and Gedeon Richter</td></tr><tr><td colspan="10" valign="bottom" align="center" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Fava et al, 2015<xref rid="b38-ndt-14-103" ref-type="bibr">38</xref> (NCT01098240)</td><td valign="top" align="left" rowspan="1" colspan="1">CP-601,927 2&#x02013;4 mg</td><td valign="top" align="left" rowspan="1" colspan="1">6 weeks</td><td valign="top" align="left" rowspan="1" colspan="1">162</td><td valign="top" align="left" rowspan="1" colspan="1">1&#x02013;3 historical ADTs + 1 prospective SSRI</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;50% improved on ATRQ</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;50% reduction in HAM-D<sub>17</sub> total score from start of prospective treatment to week 8; HAM-D<sub>17</sub> total score &#x02265;16 at week 8</td><td valign="top" align="left" rowspan="1" colspan="1">MADRS total</td><td valign="top" align="left" rowspan="1" colspan="1">25 outpatient sites in the US</td><td valign="top" align="left" rowspan="1" colspan="1">Pfizer</td></tr><tr><td colspan="10" valign="bottom" align="center" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Vieta et al, 2014<xref rid="b39-ndt-14-103" ref-type="bibr">39</xref> (NCT01157078, NCT01180400)</td><td valign="top" align="left" rowspan="1" colspan="1">Dexmecamylamine 2&#x02013;8 mg (2 studies)</td><td valign="top" align="left" rowspan="1" colspan="1">8 weeks</td><td valign="top" align="left" rowspan="1" colspan="1">319, 295</td><td valign="top" align="left" rowspan="1" colspan="1">0&#x02013;1 historical ADTs + 1 prospective SSRI/SNRI</td><td valign="top" align="left" rowspan="1" colspan="1">Not specified</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;50% reduction in HAM-D<sub>17</sub> total score from start of prospective treatment to week 8; HAM-D<sub>17</sub> total score &#x02265;16 and CGI-S score &#x02265;4 at week 8</td><td valign="top" align="left" rowspan="1" colspan="1">MADRS total</td><td valign="top" align="left" rowspan="1" colspan="1">70 outpatient sites in India and the US; 80 outpatient sites in Europe</td><td valign="top" align="left" rowspan="1" colspan="1">AstraZeneca and Targacept</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">M&#x000f6;ller et al, 2015<xref rid="b40-ndt-14-103" ref-type="bibr">40</xref> (NCT01153347, NCT01197508)</td><td valign="top" align="left" rowspan="1" colspan="1">Dexmecamylamine 0.2 mg/1 mg/2 mg/4 mg/8 mg (across 2 studies)</td><td valign="top" align="left" rowspan="1" colspan="1">8 weeks</td><td valign="top" align="left" rowspan="1" colspan="1">641, 696</td><td valign="top" align="left" rowspan="1" colspan="1">0&#x02013;1 historical ADTs + 1 prospective SSRI/SNRI</td><td valign="top" align="left" rowspan="1" colspan="1">Not specified</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;50% reduction in HAM-D<sub>17</sub> total score from start of prospective treatment to week 8; HAM-D<sub>17</sub> total score &#x02265;16 and CGI-S score &#x02265;4 at week 8</td><td valign="top" align="left" rowspan="1" colspan="1">MADRS total</td><td valign="top" align="left" rowspan="1" colspan="1">114 outpatient sites in India and the US; 132 outpatient sites in Europe, South Africa, and South America</td><td valign="top" align="left" rowspan="1" colspan="1">AstraZeneca and Targacept</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Tummala et al, 2015<xref rid="b41-ndt-14-103" ref-type="bibr">41</xref> (NCT01152554)</td><td valign="top" align="left" rowspan="1" colspan="1">Dexmecamylamine 2&#x02013;8 mg</td><td valign="top" align="left" rowspan="1" colspan="1">52 weeks</td><td valign="top" align="left" rowspan="1" colspan="1">813 (769 de novo<xref ref-type="table-fn" rid="tfn7-ndt-14-103">g</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">0&#x02013;1 historical ADTs + 1 prospective SSRI/SNRI</td><td valign="top" align="left" rowspan="1" colspan="1">Not specified</td><td valign="top" align="left" rowspan="1" colspan="1">De novo patients<xref ref-type="table-fn" rid="tfn7-ndt-14-103">g</xref>: HAM-D<sub>17</sub> total score &#x02265;10 and CGI-S score &#x02265;3 at week 6 of prospective treatment</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable (safety)</td><td valign="top" align="left" rowspan="1" colspan="1">115 outpatient sites in the US</td><td valign="top" align="left" rowspan="1" colspan="1">AstraZeneca</td></tr><tr><td colspan="10" valign="bottom" align="center" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ball et al, 2014<xref rid="b42-ndt-14-103" ref-type="bibr">42</xref> (NCT00840034)</td><td valign="top" align="left" rowspan="1" colspan="1">Edivoxetine 6&#x02013;18 mg</td><td valign="top" align="left" rowspan="1" colspan="1">8 weeks</td><td valign="top" align="left" rowspan="1" colspan="1">227</td><td valign="top" align="left" rowspan="1" colspan="1">1 ongoing SSRI</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="left" rowspan="1" colspan="1">Investigator judgment at screening; &#x0003c;25% reduction in QIDS-SR<sub>16</sub> score from start of adjunctive placebo phase to week 2</td><td valign="top" align="left" rowspan="1" colspan="1">MADRS total</td><td valign="top" align="left" rowspan="1" colspan="1">25 outpatient sites in the US</td><td valign="top" align="left" rowspan="1" colspan="1">Eli Lilly and Company</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ball et al, 2016<xref rid="b43-ndt-14-103" ref-type="bibr">43</xref> (NCT01173601, NCT01187407, NCT01185340)</td><td valign="top" align="left" rowspan="1" colspan="1">Edivoxetine 6 mg/12 mg/12&#x02013;18 mg/18 mg (across 3 studies)</td><td valign="top" align="left" rowspan="1" colspan="1">8 weeks</td><td valign="top" align="left" rowspan="1" colspan="1">701, 689, 449</td><td valign="top" align="left" rowspan="1" colspan="1">1 ongoing SSRI</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="left" rowspan="1" colspan="1">Investigator judgment at screening and start of adjunctive placebo phase; &#x0003c;25% reduction in MADRS total score from start of adjunctive placebo phase to week 3; MADRS total score &#x02265;14 at week 3</td><td valign="top" align="left" rowspan="1" colspan="1">MADRS total</td><td valign="top" align="left" rowspan="1" colspan="1">Multiple outpatient sites in Australia, Europe, Japan, Russia, South Africa, and the US</td><td valign="top" align="left" rowspan="1" colspan="1">Eli Lilly and Company</td></tr><tr><td colspan="10" valign="bottom" align="center" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Barbee et al, 2011<xref rid="b44-ndt-14-103" ref-type="bibr">44</xref> (NCT00901407)</td><td valign="top" align="left" rowspan="1" colspan="1">Lamotrigine 100&#x02013;400 mg</td><td valign="top" align="left" rowspan="1" colspan="1">10 weeks</td><td valign="top" align="left" rowspan="1" colspan="1">96</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02265;1 historical ADT + 1 prospective paroxetine/paroxetine CR</td><td valign="top" align="left" rowspan="1" colspan="1">Not specified</td><td valign="top" align="left" rowspan="1" colspan="1">HAM-D<sub>17</sub> total score &#x02265;15 at week 8 of prospective treatment</td><td valign="top" align="left" rowspan="1" colspan="1">MADRS total</td><td valign="top" align="left" rowspan="1" colspan="1">19 sites in the US</td><td valign="top" align="left" rowspan="1" colspan="1">GlaxoSmithKline</td></tr><tr><td colspan="10" valign="bottom" align="center" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Sanacora et al, 2017<xref rid="b45-ndt-14-103" ref-type="bibr">45</xref> (NCT01482221)</td><td valign="top" align="left" rowspan="1" colspan="1">Lanicemine 50 mg/100 mg (IV regimen)</td><td valign="top" align="left" rowspan="1" colspan="1">12 weeks (primary analysis at week 6)</td><td valign="top" align="left" rowspan="1" colspan="1">302</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02265;1 historical ADT (1 ongoing)</td><td valign="top" align="left" rowspan="1" colspan="1">Investigator judgment</td><td valign="top" align="left" rowspan="1" colspan="1">Investigator judgment</td><td valign="top" align="left" rowspan="1" colspan="1">MADRS total</td><td valign="top" align="left" rowspan="1" colspan="1">49 outpatient sites in Chile, Europe, South Africa, and the US</td><td valign="top" align="left" rowspan="1" colspan="1">AstraZeneca</td></tr><tr><td colspan="10" valign="bottom" align="center" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Richards et al, 2016<xref rid="b46-ndt-14-103" ref-type="bibr">46</xref> (NCT01436149, NCT01436162)</td><td valign="top" align="left" rowspan="1" colspan="1">Lisdexamfetamine dimesylate 20&#x02013;70 mg (2 studies)</td><td valign="top" align="left" rowspan="1" colspan="1">8 weeks</td><td valign="top" align="left" rowspan="1" colspan="1">404, 426</td><td valign="top" align="left" rowspan="1" colspan="1">0&#x02013;2 historical ADTs + 1 prospective SSRI/SNRI</td><td valign="top" align="left" rowspan="1" colspan="1">Not specified</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;50% reduction in MADRS total score from start of prospective treatment to week 8; MADRS total score &#x02265;18 at week 8</td><td valign="top" align="left" rowspan="1" colspan="1">MADRS total</td><td valign="top" align="left" rowspan="1" colspan="1">76 sites in Canada, Europe, Mexico and the US; 94 sites in Europe, South Africa, and the US</td><td valign="top" align="left" rowspan="1" colspan="1">Shire</td></tr><tr><td colspan="10" valign="bottom" align="center" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Thase et al, 2007<xref rid="b47-ndt-14-103" ref-type="bibr">47</xref> (NCT00035321)</td><td valign="top" align="left" rowspan="1" colspan="1">Olanzapine 6&#x02013;18 mg (as OFC; 2 studies pooled)</td><td valign="top" align="left" rowspan="1" colspan="1">8 weeks</td><td valign="top" align="left" rowspan="1" colspan="1">605 (pooled)</td><td valign="top" align="left" rowspan="1" colspan="1">1 historical ADT + 1 prospective fluoxetine</td><td valign="top" align="left" rowspan="1" colspan="1">Investigator judgment</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;25% reduction in HAM-D<sub>17</sub> total score from start of prospective treatment to week 8; HAM-D<sub>17</sub> total score &#x02265;18 at week 8; &#x02264;15% reduction in HAM-D<sub>17</sub> total score from week 7 to week 8</td><td valign="top" align="left" rowspan="1" colspan="1">MADRS total</td><td valign="top" align="left" rowspan="1" colspan="1">Multiple outpatient sites in Canada and the US</td><td valign="top" align="left" rowspan="1" colspan="1">Eli Lilly and Company</td></tr><tr><td colspan="10" valign="bottom" align="center" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mahmoud et al, 2007<xref rid="b48-ndt-14-103" ref-type="bibr">48</xref> (NCT00095134)</td><td valign="top" align="left" rowspan="1" colspan="1">Risperidone 1&#x02013;2 mg</td><td valign="top" align="left" rowspan="1" colspan="1">6 weeks</td><td valign="top" align="left" rowspan="1" colspan="1">274</td><td valign="top" align="left" rowspan="1" colspan="1">1 ongoing ADT</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="left" rowspan="1" colspan="1">CGI-S score &#x02265;4 and CDS score &#x02265;20 at week 4 of prospective phase</td><td valign="top" align="left" rowspan="1" colspan="1">HAM-D<sub>17</sub> total</td><td valign="top" align="left" rowspan="1" colspan="1">75 outpatient sites in the US</td><td valign="top" align="left" rowspan="1" colspan="1">Ortho-McNeil-Janssen</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold></p></fn><fn id="tfn1-ndt-14-103"><label>a</label><p>&#x0201c;Historical&#x0201d; describes an ADT that was discontinued prior to study enrollment.</p></fn><fn id="tfn2-ndt-14-103"><label>b</label><p>&#x0201c;Prospective&#x0201d; describes an ADT that was initiated during the study, whereas &#x0201c;ongoing&#x0201d; describes an ADT that was initiated prior to study enrollment and was continued during the study.</p></fn><fn id="tfn3-ndt-14-103"><label>c</label><p>The manuscript states that any one of these criteria is sufficient; however, by comparison with the other aripiprazole studies, we assume this is an error.</p></fn><fn id="tfn4-ndt-14-103"><label>d</label><p>In addition, where available, a patient-rated MADRS total score &#x02265;23 at screening, with a permitted discrepancy of &#x02264;7 points versus the clinician-rated MADRS total score.</p></fn><fn id="tfn5-ndt-14-103"><label>e</label><p>Revised criteria following a protocol amendment.</p></fn><fn id="tfn6-ndt-14-103"><label>f</label><p>Two-stage study design: 1) patients were randomized to placebo or active treatment; 2) placebo non-responders in stage 1 were re-randomized to placebo or active treatment.</p></fn><fn id="tfn7-ndt-14-103"><label>g</label><p>Study also rolled-over a small number of patients from two acute studies (NCT01157078 and NCT01153347).</p></fn><fn id="tfn8-ndt-14-103"><p><bold>Abbreviations:</bold> ADT, antidepressant treatment; ATHF, Antidepressant Treatment History Form; ATRQ, Massachusetts General Hospital Antidepressant Treatment Response Questionnaire; CDS, Carroll Depression Scale; CGI-I/S, Clinical Global Impressions &#x02013; Improvement/Severity of illness; CR, controlled release; HAM-D<sub>17</sub>, 17-item Hamilton Depression Rating Scale; IV, intravenous; MADRS, Montgomery&#x02013;&#x000c5;sberg Depression Rating Scale; MR, modified release; OFC, olanzapine&#x02013;fluoxetine combination; QIDS-SR<sub>16</sub>, 16-item Quick Inventory of Depressive Symptomatology (Self-Report); SNRI, serotonin&#x02013;norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-ndt-14-103" position="float"><label>Table 2</label><caption><p>Change from baseline to endpoint in self-rated functioning scale scores (for the population who received &#x02265;1 dose of randomized treatment and had &#x02265;1 post-baseline efficacy evaluation)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" valign="top" align="left" colspan="1">Reference</th><th rowspan="3" valign="top" align="left" colspan="1">Treatment arm</th><th colspan="6" valign="top" align="left" rowspan="1">SDS summary score
<hr/></th><th colspan="2" valign="top" align="left" rowspan="1">SDS work/studies
<hr/></th><th colspan="2" valign="top" align="left" rowspan="1">SDS social life
<hr/></th><th colspan="2" valign="top" align="left" rowspan="1">SDS family life
<hr/></th></tr><tr><th colspan="2" valign="top" align="left" rowspan="1">Baseline
<hr/></th><th colspan="3" valign="top" align="left" rowspan="1">Change to endpoint
<hr/></th><th colspan="2" valign="top" align="left" rowspan="1">Change to endpoint
<hr/></th><th colspan="2" valign="top" align="left" rowspan="1">Change to endpoint
<hr/></th><th colspan="2" valign="top" align="left" rowspan="1">Change to endpoint
<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">n</th><th valign="top" align="left" rowspan="1" colspan="1">Mean (SD)</th><th valign="top" align="left" rowspan="1" colspan="1">n</th><th valign="top" align="left" rowspan="1" colspan="1">Mean (SE)</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>p</italic>-value versus placebo</th><th valign="top" align="left" rowspan="1" colspan="1">Mean (SE)</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>p</italic>-value versus placebo</th><th valign="top" align="left" rowspan="1" colspan="1">Mean (SE)</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>p</italic>-value versus placebo</th><th valign="top" align="left" rowspan="1" colspan="1">Mean (SE)</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>p</italic>-value versus placebo</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Aripiprazole</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><bold>SDS mean</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Berman et al, 200729</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">164</td><td valign="top" align="left" rowspan="1" colspan="1">5.4 (0.2)<xref ref-type="table-fn" rid="tfn10-ndt-14-103">a</xref></td><td valign="top" align="left" rowspan="1" colspan="1">164</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.7 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.7 (0.3)<xref ref-type="table-fn" rid="tfn11-ndt-14-103">b</xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.8 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.5 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2&#x02013;20 mg</td><td valign="top" align="left" rowspan="1" colspan="1">167</td><td valign="top" align="left" rowspan="1" colspan="1">5.7 (0.2)<xref ref-type="table-fn" rid="tfn10-ndt-14-103">a</xref></td><td valign="top" align="left" rowspan="1" colspan="1">167</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.1 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.055</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.7 (0.2)<xref ref-type="table-fn" rid="tfn12-ndt-14-103">c</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.98</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.4(0.2)</td><td valign="top" align="left" style="background-color:#CBE29F" rowspan="1" colspan="1">0.030</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.1 (0.2)</td><td valign="top" align="left" style="background-color:#CBE29F" rowspan="1" colspan="1">0.017</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Marcus et al, 2008<xref rid="b30-ndt-14-103" ref-type="bibr">30</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">168</td><td valign="top" align="left" rowspan="1" colspan="1">5.4 (0.2)<xref ref-type="table-fn" rid="tfn10-ndt-14-103">a</xref></td><td valign="top" align="left" rowspan="1" colspan="1">168</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.7 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.4 (0.2)<xref ref-type="table-fn" rid="tfn13-ndt-14-103">d</xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.6 (0.2)<xref ref-type="table-fn" rid="tfn14-ndt-14-103">e</xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.0 (0.2)<xref ref-type="table-fn" rid="tfn14-ndt-14-103">e</xref></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2&#x02013;20 mg</td><td valign="top" align="left" rowspan="1" colspan="1">180</td><td valign="top" align="left" rowspan="1" colspan="1">5.1 (0.2)<xref ref-type="table-fn" rid="tfn10-ndt-14-103">a</xref></td><td valign="top" align="left" rowspan="1" colspan="1">180</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.3 (0.2)</td><td valign="top" align="left" style="background-color:#CBE29F" rowspan="1" colspan="1">0.012</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.5 (0.2)<xref ref-type="table-fn" rid="tfn15-ndt-14-103">f</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.62</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.4 (0.2)<xref ref-type="table-fn" rid="tfn16-ndt-14-103">g</xref></td><td valign="top" align="left" style="background-color:#CBE29F" rowspan="1" colspan="1">0.002</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.8 (0.2)<xref ref-type="table-fn" rid="tfn16-ndt-14-103">g</xref></td><td valign="top" align="left" style="background-color:#CBE29F" rowspan="1" colspan="1">0.002</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Berman et al, 2009<xref rid="b31-ndt-14-103" ref-type="bibr">31</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">160</td><td valign="top" align="left" rowspan="1" colspan="1">5.9 (0.2)<xref ref-type="table-fn" rid="tfn10-ndt-14-103">a</xref></td><td valign="top" align="left" rowspan="1" colspan="1">160</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.8 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.7 (0.3)<xref ref-type="table-fn" rid="tfn17-ndt-14-103">h</xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.7 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.8 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2&#x02013;20 mg</td><td valign="top" align="left" rowspan="1" colspan="1">160</td><td valign="top" align="left" rowspan="1" colspan="1">5.7 (0.2)<xref ref-type="table-fn" rid="tfn10-ndt-14-103">a</xref></td><td valign="top" align="left" rowspan="1" colspan="1">160</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.2 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.075</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.8 (0.3)<xref ref-type="table-fn" rid="tfn18-ndt-14-103">i</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.79</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.2 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.052</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.4 (0.2)</td><td valign="top" align="left" style="background-color:#CBE29F" rowspan="1" colspan="1">0.037</td></tr><tr><td rowspan="3" valign="top" align="left" colspan="1">Kamijima et al, 2013<xref rid="b32-ndt-14-103" ref-type="bibr">32</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">195</td><td valign="top" align="left" rowspan="1" colspan="1">5.3 (0.1)<xref ref-type="table-fn" rid="tfn10-ndt-14-103">a</xref></td><td valign="top" align="left" rowspan="1" colspan="1">193</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.5 (0.1)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.4 (0.1)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.6 (0.1)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.3 (0.1)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">3 mg</td><td valign="top" align="left" rowspan="1" colspan="1">197</td><td valign="top" align="left" rowspan="1" colspan="1">5.0 (0.1)<xref ref-type="table-fn" rid="tfn10-ndt-14-103">a</xref></td><td valign="top" align="left" rowspan="1" colspan="1">197</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.0 (0.1)</td><td valign="top" align="left" style="background-color:#CBE29F" rowspan="1" colspan="1">0.001</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.9 (0.1)</td><td valign="top" align="left" style="background-color:#CBE29F" rowspan="1" colspan="1">0.003</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.1 (0.1)</td><td valign="top" align="left" style="background-color:#CBE29F" rowspan="1" colspan="1">0.003</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.9 (0.1)</td><td valign="top" align="left" style="background-color:#CBE29F" rowspan="1" colspan="1">0.003</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">3&#x02013;15 mg</td><td valign="top" align="left" rowspan="1" colspan="1">194</td><td valign="top" align="left" rowspan="1" colspan="1">5.0 (0.1)<xref ref-type="table-fn" rid="tfn10-ndt-14-103">a</xref></td><td valign="top" align="left" rowspan="1" colspan="1">193</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.0 (0.1)</td><td valign="top" align="left" style="background-color:#CBE29F" rowspan="1" colspan="1">&#x0003c;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.0 (0.1)</td><td valign="top" align="left" style="background-color:#CBE29F" rowspan="1" colspan="1">&#x0003c;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.2 (0.1)</td><td valign="top" align="left" style="background-color:#CBE29F" rowspan="1" colspan="1">&#x0003c;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.9 (0.1)</td><td valign="top" align="left" style="background-color:#CBE29F" rowspan="1" colspan="1">0.003</td></tr><tr><td colspan="13" valign="bottom" align="center" rowspan="1">
<hr/></td></tr><tr><td colspan="2" valign="top" align="left" rowspan="1"><bold>Basimglurant MR</bold></td><td colspan="2" valign="top" align="left" rowspan="1"><bold>SDS sum of items 2 and 3</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td rowspan="3" valign="top" align="left" colspan="1">Quiroz et al, 2016<xref rid="b33-ndt-14-103" ref-type="bibr">33</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">109<xref ref-type="table-fn" rid="tfn19-ndt-14-103">j</xref></td><td valign="top" align="left" rowspan="1" colspan="1">13.2 (3.7)</td><td valign="top" align="left" rowspan="1" colspan="1">109</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;5.1 (0.6)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">0.5 mg</td><td valign="top" align="left" rowspan="1" colspan="1">112<xref ref-type="table-fn" rid="tfn19-ndt-14-103">j</xref></td><td valign="top" align="left" rowspan="1" colspan="1">13.8 (4.0)</td><td valign="top" align="left" rowspan="1" colspan="1">112</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;5.1 (0.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0.94</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">1.5 mg</td><td valign="top" align="left" rowspan="1" colspan="1">111<xref ref-type="table-fn" rid="tfn19-ndt-14-103">j</xref></td><td valign="top" align="left" rowspan="1" colspan="1">13.5 (3.6)</td><td valign="top" align="left" rowspan="1" colspan="1">111</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;6.4 (0.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0.09</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="13" valign="bottom" align="center" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Brexpiprazole</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><bold>SDS mean</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Thase et al, 2015<xref rid="b34-ndt-14-103" ref-type="bibr">34</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">191<xref ref-type="table-fn" rid="tfn19-ndt-14-103">j</xref></td><td valign="top" align="left" rowspan="1" colspan="1">6.3 (2.1)</td><td valign="top" align="left" rowspan="1" colspan="1">178</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.9 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.0 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.0 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.7 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2 mg</td><td valign="top" align="left" rowspan="1" colspan="1">188<xref ref-type="table-fn" rid="tfn19-ndt-14-103">j</xref></td><td valign="top" align="left" rowspan="1" colspan="1">6.0 (2.0)</td><td valign="top" align="left" rowspan="1" colspan="1">175</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.4 (0.2)</td><td valign="top" align="left" style="background-color:#CBE29F" rowspan="1" colspan="1">0.035</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.1 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.61</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.6 (0.2)</td><td valign="top" align="left" style="background-color:#CBE29F" rowspan="1" colspan="1">0.022</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.3 (0.2)</td><td valign="top" align="left" style="background-color:#CBE29F" rowspan="1" colspan="1">0.011</td></tr><tr><td rowspan="3" valign="top" align="left" colspan="1">Thase et al, 2015<xref rid="b35-ndt-14-103" ref-type="bibr">35</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">221<xref ref-type="table-fn" rid="tfn20-ndt-14-103">k</xref></td><td valign="top" align="left" rowspan="1" colspan="1">5.6 (1.9)</td><td valign="top" align="left" rowspan="1" colspan="1">203</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.8 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.7 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.9 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.8 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">1 mg</td><td valign="top" align="left" rowspan="1" colspan="1">226<xref ref-type="table-fn" rid="tfn20-ndt-14-103">k</xref></td><td valign="top" align="left" rowspan="1" colspan="1">5.9 (2.0)</td><td valign="top" align="left" rowspan="1" colspan="1">211</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.3 (0.2)</td><td valign="top" align="left" style="background-color:#CBE29F" rowspan="1" colspan="1">0.016</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.1 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.082</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.3 (0.2)</td><td valign="top" align="left" style="background-color:#CBE29F" rowspan="1" colspan="1">0.035</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.3 (0.2)</td><td valign="top" align="left" style="background-color:#CBE29F" rowspan="1" colspan="1">0.019</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">3 mg</td><td valign="top" align="left" rowspan="1" colspan="1">230<xref ref-type="table-fn" rid="tfn20-ndt-14-103">k</xref></td><td valign="top" align="left" rowspan="1" colspan="1">5.7 (2.2)</td><td valign="top" align="left" rowspan="1" colspan="1">213</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.3 (0.2)</td><td valign="top" align="left" style="background-color:#CBE29F" rowspan="1" colspan="1">0.019</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.9 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.30</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.4 (0.2)</td><td valign="top" align="left" style="background-color:#CBE29F" rowspan="1" colspan="1">0.028</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.4 (0.2)</td><td valign="top" align="left" style="background-color:#CBE29F" rowspan="1" colspan="1">0.0077</td></tr><tr><td colspan="13" valign="bottom" align="center" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Buprenorphine + samidorphan</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td rowspan="3" valign="top" align="left" colspan="1">Fava et al, 2016<xref rid="b36-ndt-14-103" ref-type="bibr">36</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2 mg + 2 mg</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">8 mg + 8 mg</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="13" valign="bottom" align="center" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Cariprazine</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><bold>SDS total</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td rowspan="3" valign="top" align="left" colspan="1">Durgam et al, 2016<xref rid="b37-ndt-14-103" ref-type="bibr">37</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">264</td><td valign="top" align="left" rowspan="1" colspan="1">18.5 (4.7)</td><td valign="top" align="left" rowspan="1" colspan="1">264</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;6.6 (0.5)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;2.3</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">1&#x02013;2 mg</td><td valign="top" align="left" rowspan="1" colspan="1">273</td><td valign="top" align="left" rowspan="1" colspan="1">18.7 (4.7)</td><td valign="top" align="left" rowspan="1" colspan="1">273</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;7.7 (0.5)</td><td valign="top" align="left" rowspan="1" colspan="1">0.24</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2&#x02013;4.5 mg</td><td valign="top" align="left" rowspan="1" colspan="1">271</td><td valign="top" align="left" rowspan="1" colspan="1">18.8 (4.8)</td><td valign="top" align="left" rowspan="1" colspan="1">271</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;8.0 (0.5)</td><td valign="top" align="left" rowspan="1" colspan="1">0.11</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;2.9</td><td valign="top" align="left" style="background-color:#CBE29F" rowspan="1" colspan="1">0.014</td></tr><tr><td colspan="13" valign="bottom" align="center" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>CP-601, 927</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><bold>SDS total</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Fava et al, 2015<xref rid="b38-ndt-14-103" ref-type="bibr">38</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">85</td><td valign="top" align="left" rowspan="1" colspan="1">18.5 (5.3)</td><td valign="top" align="left" rowspan="1" colspan="1">85</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;5.7 (8.2)<xref ref-type="table-fn" rid="tfn21-ndt-14-103">l</xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>2</italic>&#x02013;4 mg</td><td valign="top" align="left" rowspan="1" colspan="1">77</td><td valign="top" align="left" rowspan="1" colspan="1">19.0 (5.9)</td><td valign="top" align="left" rowspan="1" colspan="1">77</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;6.6 (8.0)<xref ref-type="table-fn" rid="tfn21-ndt-14-103">l</xref></td><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td colspan="13" valign="bottom" align="center" rowspan="1">
<hr/></td></tr><tr><td colspan="2" valign="top" align="left" rowspan="1"><bold>Dexmecamylamine</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>SDS total</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td rowspan="4" valign="top" align="left" colspan="1">Vieta et al, 2014<xref rid="b35-ndt-14-103" ref-type="bibr">35</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">151</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;5.5 (0.7)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.7 (0.2)<xref ref-type="table-fn" rid="tfn22-ndt-14-103">m</xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.9 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;2.0 (0.3)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2&#x02013;8 mg</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">143</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;6.1 (0.7)</td><td valign="top" align="left" rowspan="1" colspan="1">0.42</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;2.0 (0.2)<xref ref-type="table-fn" rid="tfn23-ndt-14-103">n</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.21</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.9 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.93</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;2.1 (0.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.76</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">142</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;5.8 (0.5)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.8 (0.2)<xref ref-type="table-fn" rid="tfn24-ndt-14-103">o</xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.9 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;2.0 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2&#x02013;8 mg</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">138</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;5.8 (0.5)</td><td valign="top" align="left" rowspan="1" colspan="1">0.96</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;2.2 (0.3)<xref ref-type="table-fn" rid="tfn25-ndt-14-103">p</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.20</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;2.0 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.76</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.9 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.62</td></tr><tr><td rowspan="8" valign="top" align="left" colspan="1">M&#x000f6;ller et al, 2015<xref rid="b40-ndt-14-103" ref-type="bibr">40</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">153</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;4.9 (0.6)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.7 (0.2)<xref ref-type="table-fn" rid="tfn26-ndt-14-103">q</xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.9 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.6 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">1 mg</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">152</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;5.5 (0.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0.42</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.7 (0.2)<xref ref-type="table-fn" rid="tfn27-ndt-14-103">r</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.95</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.9 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.92</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.9 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.21</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">4 mg</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">148</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;5.5 (0.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0.49</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.8 (0.2)<xref ref-type="table-fn" rid="tfn28-ndt-14-103">s</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.87</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.9 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.97</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.8 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.34</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">8 mg</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">149</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;4.5 (0.7)</td><td valign="top" align="left" rowspan="1" colspan="1">0.60</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.7 (0.2)<xref ref-type="table-fn" rid="tfn29-ndt-14-103">t</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.79</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.6(0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.24</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.6 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.97</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">172</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;7.1 (0.6)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;2.1 (0.2)<xref ref-type="table-fn" rid="tfn30-ndt-14-103">u</xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;2.4 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;2.3 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">0.2 mg</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">171</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;6.1 (0.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0.18</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;2.0 (0.2)<xref ref-type="table-fn" rid="tfn31-ndt-14-103">v</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.91</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;2.1 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.25</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;2.0 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.17</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2 mg</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">168</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;6.3 (0.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0.33</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.8 (0.2)<xref ref-type="table-fn" rid="tfn32-ndt-14-103">w</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.45</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;2.2 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.50</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;2.1 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.40</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">8 mg</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">163</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;6.2 (0.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0.27</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.9 (0.2)<xref ref-type="table-fn" rid="tfn33-ndt-14-103">x</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.66</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;2.2 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.44</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;2.0 (0.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.20</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Tummala et al, 2015<xref rid="b41-ndt-14-103" ref-type="bibr">41</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">70</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;7.4 (7.5)<xref ref-type="table-fn" rid="tfn21-ndt-14-103">l</xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2&#x02013;8 mg</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">185</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;7.0 (7.9)<xref ref-type="table-fn" rid="tfn21-ndt-14-103">l</xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="13" valign="bottom" align="center" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Edivoxetine</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><bold>SDS total<xref ref-type="table-fn" rid="tfn34-ndt-14-103">y</xref></bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Ball et al, 2014<xref rid="b42-ndt-14-103" ref-type="bibr">42</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">71<xref ref-type="table-fn" rid="tfn20-ndt-14-103">k</xref></td><td valign="top" align="left" rowspan="1" colspan="1">19.2 (6.8)</td><td valign="top" align="left" rowspan="1" colspan="1">68</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;2.6</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.4</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.0</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.0</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">6&#x02013;18 mg</td><td valign="top" align="left" rowspan="1" colspan="1">67<xref ref-type="table-fn" rid="tfn20-ndt-14-103">k</xref></td><td valign="top" align="left" rowspan="1" colspan="1">17.9 (6.9)</td><td valign="top" align="left" rowspan="1" colspan="1">63</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;6.0</td><td valign="top" align="left" style="background-color:#CBE29F" rowspan="1" colspan="1">0.039</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.9</td><td valign="top" align="left" rowspan="1" colspan="1">0.10</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;2.1</td><td valign="top" align="left" style="background-color:#CBE29F" rowspan="1" colspan="1">0.046</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.9</td><td valign="top" align="left" rowspan="1" colspan="1">0.11</td></tr><tr><td rowspan="8" valign="top" align="left" colspan="1">Ball et al, 2016<xref rid="b43-ndt-14-103" ref-type="bibr">43</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">P: 690<xref ref-type="table-fn" rid="tfn20-ndt-14-103">k</xref></td><td valign="top" align="left" rowspan="1" colspan="1">P: 18.1 (6.1)</td><td valign="top" align="left" rowspan="1" colspan="1">240</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;4.5 (0.4)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">12 mg</td><td valign="top" align="left" rowspan="1" colspan="1">E: 1,149<xref ref-type="table-fn" rid="tfn20-ndt-14-103">k</xref></td><td valign="top" align="left" rowspan="1" colspan="1">E: 18.2 (5.8)</td><td valign="top" align="left" rowspan="1" colspan="1">231</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;5.4 (0.4)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">18 mg</td><td valign="top" align="left" rowspan="1" colspan="1">(pooled)</td><td valign="top" align="left" rowspan="1" colspan="1">(pooled)</td><td valign="top" align="left" rowspan="1" colspan="1">230</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;5.3 (0.4)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">231</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;4.3 (0.4)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">6 mg</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">226</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;6.3 (0.4)</td><td valign="top" align="left" style="background-color:#CBE29F" rowspan="1" colspan="1">&#x02264;0.05</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">12&#x02013;18 mg</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">232</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;5.3 (0.4)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">219</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;4.4 (0.5)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">12&#x02013;18 mg</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">230</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;4.5 (0.5)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="13" valign="bottom" align="center" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Lamotrigine</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Barbee et al, 2011<xref rid="b44-ndt-14-103" ref-type="bibr">44</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">100&#x02013;400 mg</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="13" valign="bottom" align="center" rowspan="1">
<hr/></td></tr><tr><td colspan="2" valign="top" align="left" rowspan="1"><bold>Lanicemine (IV regimen)</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>SDS total</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td rowspan="3" valign="top" align="left" colspan="1">Sanacoraet al, 2017<xref rid="b45-ndt-14-103" ref-type="bibr">45</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">97</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;6.9 (1.0)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">50 mg</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">101</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;7.1 (1.0)</td><td valign="top" align="left" rowspan="1" colspan="1">0.89</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">100 mg</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">100</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;6.9 (1.0)</td><td valign="top" align="left" rowspan="1" colspan="1">0.99</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="13" valign="bottom" align="center" rowspan="1">
<hr/></td></tr><tr><td colspan="2" valign="top" align="left" rowspan="1"><bold>Lisdexamfetamine dimesylate</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>SDS total</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td rowspan="4" valign="top" align="left" colspan="1">Richardset al, 20I6<xref rid="b46-ndt-14-103" ref-type="bibr">46</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">198</td><td valign="top" align="left" rowspan="1" colspan="1">15.6 (5.7)</td><td valign="top" align="left" rowspan="1" colspan="1">164</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;4.3 (&#x02212;5.3, &#x02212;3.3)<xref ref-type="table-fn" rid="tfn35-ndt-14-103">z</xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">20&#x02013;70 mg</td><td valign="top" align="left" rowspan="1" colspan="1">198</td><td valign="top" align="left" rowspan="1" colspan="1">15.9 (6.0)</td><td valign="top" align="left" rowspan="1" colspan="1">162</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;4.7 (&#x02212;5.6, &#x02212;3.7)<xref ref-type="table-fn" rid="tfn35-ndt-14-103">z</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.58</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">213</td><td valign="top" align="left" rowspan="1" colspan="1">16.8 (5.8)</td><td valign="top" align="left" rowspan="1" colspan="1">189</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;4.3 (&#x02212;5.2, &#x02212;3.4)<xref ref-type="table-fn" rid="tfn35-ndt-14-103">z</xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">20&#x02013;70 mg</td><td valign="top" align="left" rowspan="1" colspan="1">209</td><td valign="top" align="left" rowspan="1" colspan="1">16.8 (5.3)</td><td valign="top" align="left" rowspan="1" colspan="1">180</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;4.9 (&#x02212;5.8, &#x02212;4.0)<xref ref-type="table-fn" rid="tfn35-ndt-14-103">z</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.35</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td colspan="13" valign="bottom" align="center" rowspan="1">
<hr/></td></tr><tr><td colspan="2" valign="top" align="left" rowspan="1"><bold>Olanzapine (as OFC; 2 studies pooled)</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Thase et al, 2007<xref rid="b47-ndt-14-103" ref-type="bibr">47</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Fluoxetine</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">203</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.1 (2.6)<xref ref-type="table-fn" rid="tfn21-ndt-14-103">l</xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.2 (2.6)<xref ref-type="table-fn" rid="tfn21-ndt-14-103">l</xref></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">6&#x02013;18 mg</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">198</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.46</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.6 (2.8)<xref ref-type="table-fn" rid="tfn21-ndt-14-103">l</xref></td><td valign="top" align="left" style="background-color:#CBE29F" rowspan="1" colspan="1">0.027</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.7 (2.7)<xref ref-type="table-fn" rid="tfn21-ndt-14-103">l</xref></td><td valign="top" align="left" style="background-color:#CBE29F" rowspan="1" colspan="1">0.047</td></tr><tr><td colspan="13" valign="bottom" align="center" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Risperidone</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><bold>SDS total</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Mahmoud et al, 2007<xref rid="b48-ndt-14-103" ref-type="bibr">48</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">113</td><td valign="top" align="left" rowspan="1" colspan="1">20.2 (0.6)<xref ref-type="table-fn" rid="tfn10-ndt-14-103">a</xref></td><td valign="top" align="left" rowspan="1" colspan="1">101</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;3.9</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.8</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.5</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.4</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">1&#x02013;2 mg</td><td valign="top" align="left" rowspan="1" colspan="1">110</td><td valign="top" align="left" rowspan="1" colspan="1">19.9 (0.6)<xref ref-type="table-fn" rid="tfn10-ndt-14-103">a</xref></td><td valign="top" align="left" rowspan="1" colspan="1">100</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;7.6</td><td valign="top" align="left" style="background-color:#CBE29F" rowspan="1" colspan="1">&#x0003c;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.7</td><td valign="top" align="left" rowspan="1" colspan="1">0.12</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;2.9</td><td valign="top" align="left" style="background-color:#CBE29F" rowspan="1" colspan="1">&#x0003c;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;2.5</td><td valign="top" align="left" style="background-color:#CBE29F" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Pandina et al, 2009<xref rid="b28-ndt-14-103" ref-type="bibr">28</xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn9-ndt-14-103"><p><bold>Notes:</bold> Highlighted cells indicate <italic>p</italic>&#x02264;0.05 versus placebo.</p></fn><fn id="tfn10-ndt-14-103"><label>a</label><p>SE.</p></fn><fn id="tfn11-ndt-14-103"><label>b</label><p>n=130.</p></fn><fn id="tfn12-ndt-14-103"><label>c</label><p>n=127.</p></fn><fn id="tfn13-ndt-14-103"><label>d</label><p>n=136.</p></fn><fn id="tfn14-ndt-14-103"><label>e</label><p>n=170.</p></fn><fn id="tfn15-ndt-14-103"><label>f</label><p>n=142.</p></fn><fn id="tfn16-ndt-14-103"><label>g</label><p>n=181.</p></fn><fn id="tfn17-ndt-14-103"><label>h</label><p>n=126.</p></fn><fn id="tfn18-ndt-14-103"><label>i</label><p>n=115.</p></fn><fn id="tfn19-ndt-14-103"><label>j</label><p>For the population who received &#x02265;1 dose of randomized treatment</p></fn><fn id="tfn20-ndt-14-103"><label>k</label><p>For the randomized population.</p></fn><fn id="tfn21-ndt-14-103"><label>l</label><p>SD.</p></fn><fn id="tfn22-ndt-14-103"><label>m</label><p>n=134.</p></fn><fn id="tfn23-ndt-14-103"><label>n</label><p>n=124.</p></fn><fn id="tfn24-ndt-14-103"><label>o</label><p>n=120.</p></fn><fn id="tfn25-ndt-14-103"><label>p</label><p>n=115.</p></fn><fn id="tfn26-ndt-14-103"><label>q</label><p>n=137.</p></fn><fn id="tfn27-ndt-14-103"><label>r</label><p>n=132.</p></fn><fn id="tfn28-ndt-14-103"><label>s</label><p>n=123.</p></fn><fn id="tfn29-ndt-14-103"><label>t</label><p>n=134.</p></fn><fn id="tfn30-ndt-14-103"><label>u</label><p>n=137.</p></fn><fn id="tfn31-ndt-14-103"><label>v</label><p>n=141.</p></fn><fn id="tfn32-ndt-14-103"><label>w</label><p>n=140.</p></fn><fn id="tfn33-ndt-14-103"><label>x</label><p>n=126.</p></fn><fn id="tfn34-ndt-14-103"><label>y</label><p>If the work/studies item was missing, the mean of the other two items was imputed to calculate the total score.</p></fn><fn id="tfn35-ndt-14-103"><label>z</label><p>95% CI.</p></fn><fn id="tfn36-ndt-14-103"><p><bold>Abbreviations:</bold> E, edivoxetine; IV, intravenous; MR, modified release; NS, not statistically significant (and <italic>p</italic>-value not reported); OFC, olanzapine&#x02013;fluoxetine combination; P, placebo; SDS, Sheehan Disability Scale.</p></fn></table-wrap-foot></table-wrap></floats-group></article>